<SEC-DOCUMENT>0001104659-24-103658.txt : 20240927
<SEC-HEADER>0001104659-24-103658.hdr.sgml : 20240927
<ACCEPTANCE-DATETIME>20240927152019
ACCESSION NUMBER:		0001104659-24-103658
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20240927
DATE AS OF CHANGE:		20240927

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Theriva Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-282024
		FILM NUMBER:		241334282

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Synthetic Biologics, Inc.
		DATE OF NAME CHANGE:	20120305

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>tm2425095d1_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Filed Pursuant to Rule 424(b)(5)</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%"><B>PROSPECTUS </B></TD>
  <TD STYLE="text-align: right; width: 50%"><B>Reg. No. 333-282024</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm2423565d1_s1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>918,600 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><B>1,428,600</B> Common Warrants to Purchase
Up to <B>1,428,600</B> Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>510,000 Pre-Funded Warrants to Purchase Up
to 510,000 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to <B>1,938,600 </B> Shares of Common Stock Underlying
the Common Warrants and Pre-Funded Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are offering on a best efforts basis 918,600 shares of our common stock, par value $0.001 (the &ldquo;Common
Stock&rdquo;), and 510,000 pre-funded warrants (the &ldquo;Pre-Funded Warrants&rdquo;) to purchase up to 510,000 shares of Common Stock,
together with accompanying warrants to purchase up to 1,428,600 shares of our Common Stock. Each share of Common Stock, or a pre-funded
warrant in lieu thereof, is being sold together with a common warrant to purchase one share of Common Stock (the &ldquo;Common Warrant&rdquo;).
The shares of Common Stock and Common Warrants are immediately separable and will be issued separately in this offering, but must be purchased
together in this offering. The public offering price for each share of Common Stock and accompanying Common Warrant is $1.75. Each Common
Warrant will have an exercise price per share of $2.00 and will be immediately exercisable. The Common Warrants will expire on the 5-year anniversary of the original issuance
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also offering Pre-Funded Warrants to each purchaser whose purchase
of shares of Common Stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties,
beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Common Stock immediately following
the consummation of this offering, in lieu of shares of Common Stock that would otherwise result in such purchaser&rsquo;s beneficial
ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Common Stock. The public offering price of
each Pre-Funded Warrant and accompanying Common Warrant is $1.7499, which is equal to the price of one share of Common Stock and accompanying
Common Warrant in this offering, minus $0.0001, and the exercise price of each Pre-Funded Warrant will be $0.0001 per share. The Pre-Funded
Warrants will be immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.
The Pre-Funded Warrants and Common Warrants are immediately separable and will be issued separately in this offering, but must be purchased
together in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have engaged A.G.P./Alliance Global Partners
(&ldquo;A.G.P.&rdquo; or the &ldquo;Placement Agent&rdquo;), to act as our sole placement agent, to use its reasonable best efforts to
arrange for the sale of the securities offered by this prospectus. The Placement Agent is not purchasing or selling any of the securities
we are offering, and the Placement Agent is not required to arrange the purchase or sale of any specific number or dollar amount of securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities will be offered at a fixed
price and are expected to be issued in a single closing. The offering will terminate on October 15, 2024, unless (i)&nbsp;the
closing occurs prior thereto or (ii)&nbsp;we decide to terminate the offering prior thereto (which we may do at any time in our
discretion). Investors purchasing securities offered hereby will have the option to execute a securities purchase agreement with us.
We expect that the closing of the offering will  occur on or about September 27, 2024 but no later than one trading day after
we price the securities offered hereby. When we price the securities, we
will simultaneously enter into securities purchase agreements relating to the offering with those investors who so choose. The
offering will settle delivery versus payment (&ldquo;DVP&rdquo;)/receipt versus payment (&ldquo;RVP&rdquo;). That is, on the closing
date, we will issue the shares of Common Stock directly to the account(s)&nbsp;at the Placement Agent identified by each purchaser;
upon receipt of such shares, the Placement Agent shall promptly electronically deliver such shares to the applicable purchaser, and
payment therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since we will deliver the securities to be issued
in this offering upon our receipt of investor funds, we and the Placement Agent have not made any arrangements to place investor funds
in an escrow account or trust account. Because this is a best-efforts offering, the Placement Agent does not have an obligation to purchase
any securities, and, as a result, there is a possibility that we may not be able to sell the securities. There is no minimum offering
requirement as a condition of closing of this offering. Because there is no minimum offering amount required as a condition to closing
this offering, we may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received
by us, and investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to
pursue our business goals described in this prospectus. In addition, because there is no escrow account and no minimum offering amount,
investors could be in a position where they have invested in our company, but we are unable to fulfill all of our contemplated objectives
due to a lack of interest in this offering. Further, any proceeds from the sale of securities offered by us will be available for our
immediate use, despite uncertainty about whether we would be able to use such funds to effectively implement our business plan. See the
section entitled &ldquo;Risk Factors&rdquo; for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Common Stock is listed on the NYSE American
under the symbol &ldquo;TOVX.&rdquo; On September 25, 2024, the last reported sale price of our Common Stock
on the NYSE American was $2.37 per share. The public offering price per share of Common Stock and accompanying Common Warrant is $1.75,
and per Pre-Funded Warrant and accompanying Common Warrant is $1.7499. There is no established public trading market for the Common Warrants and the Pre-Funded Warrants, and we
do not expect such a market to develop. Without an active trading market, the liquidity of the Common Warrants and the Pre-Funded Warrants
will be limited. In addition, we do not intend to list the Common Warrants and the Pre-Funded Warrants on NYSE American, any other national
securities exchange or any other trading system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">On August 26, 2024, we effected a reverse stock&nbsp;split&nbsp;of
our Common Stock at a ratio of one-for-twenty five. Unless otherwise indicated, all financial information, share numbers, option numbers,
warrant numbers, other derivative security numbers and exercise prices appearing in this registration statement have been adjusted to
give effect to the reverse stock split.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Investing
in our securities involves risks. You should review carefully the risks and uncertainties described under the heading &ldquo;<I>Risk
Factors</I>&rdquo; contained in this prospectus and under similar headings in the other documents that are incorporated by reference
into this prospectus, as described beginning on page&nbsp;</B></FONT><B>6 of this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of the securities to be issued under this prospectus or determined if
this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Per Share of<BR> Common Stock<BR> and<BR> Accompanying<BR> Common<BR> Warrant</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Per Pre-Funded<BR> Warrant and<BR> Accompanying<BR> Common<BR> Warrant</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public offering price<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1.75</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1.7499</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,499,999</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement agent fees<SUP>(2)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1225</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1225</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">175,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds to us, before expenses<SUP>(3)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.6275</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.6274</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,324,999</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 97%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    combined public offering price is $1.75 per share of Common Stock and accompanying Common Warrant and $1.7499 per Pre-Funded Warrant
    and accompanying Common Warrant.&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents a cash fee equal
    to 7.0% of the aggregate purchase price paid by investors in this offering. See &ldquo;<I>Plan of Distribution</I>&rdquo; for additional
    disclosure regarding compensation payable to the Placement Agent. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does not include proceeds
    from the exercise of the Common Warrants and/or Pre-Funded Warrants in cash, if any.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Delivery of the securities is expected to be made on or about September
27, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Sole Placement Agent</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>A.G.P.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus <B>is September 25</B>, 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 95%"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="width: 5%; text-align: right"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SPECIAL NOTE REGARDING FORWARD-LOOKING
    STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_003">2</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE OFFERING</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_004">4</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_005">6</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_006">9</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIVIDEND POLICY</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_007">10</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_008">11</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF SECURITIES TO BE REGISTERED</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_009">15</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MATERIAL UNITED STATES FEDERAL INCOME
    TAX CONSIDERATIONS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_010">18</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_011">23</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_012">25</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_013">25</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND ADDITIONAL INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_014">25</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF CERTAIN INFORMATION
    BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_015">25</A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on the information that
we have provided or incorporated by reference in this prospectus. We have not authorized anyone to provide you with different or additional
information. If anyone provides you with different or additional information, you should not rely on it. You should assume that the information
in this prospectus is accurate only as of the date on the cover of the document and that any information we have incorporated by reference
is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus or any
sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We urge you to carefully read this prospectus,
together with the information incorporated herein by reference as described under the heading &ldquo;<I>Where You Can Find Additional
Information</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this prospectus, unless otherwise specified
or the context requires otherwise, we use the terms &ldquo;Theriva,&rdquo; &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo;
and &ldquo;our&rdquo; or similar references to refer to Theriva Biologics,&nbsp;Inc., a Nevada corporation, together with its consolidated
subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>SPECIAL NOTE REGARDING
FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
prospectus and the documents incorporated by reference into this prospectus include forward-looking statements within the meaning of
Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act
of 1934, as amended, or the Exchange Act, that relate to future events or our future financial performance and involve known and unknown
risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially
from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Words
such as, but not limited to, &ldquo;anticipate,&rdquo; &ldquo;aim,&rdquo; &ldquo;believe,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;continue,&rdquo;
 &ldquo;could,&rdquo; &ldquo;design,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo;
 &ldquo;plan,&rdquo; &ldquo;predict,&rdquo; &ldquo;poise,&rdquo; &ldquo;project,&rdquo; &ldquo;potential,&rdquo; &ldquo;suggest,&rdquo;
 &ldquo;should,&rdquo; &ldquo;strategy,&rdquo; &ldquo;target,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; and similar expressions
or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking
statements contain these identifying words. Although we believe that we have a reasonable basis for each forward-looking statement contained
in this prospectus and incorporated by reference into this prospectus, we caution you that these statements are based on our projections
of the future that are subject to known and unknown risks and uncertainties and other factors that may cause our actual results, level
of activity, performance or achievements expressed or implied by these forward-looking statements, to differ. The section in this prospectus
entitled &ldquo;<I>Risk Factors</I>&rdquo; and the sections in our periodic reports, including the </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000141057824000293/tmb-20231231x10k.htm" STYLE="-sec-extract: exhibit">Annual
Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2023 filed with the Securities and Exchange Commission( the &ldquo;SEC&rdquo;),
on March&nbsp;25, 2024</A> entitled &ldquo;Business,&rdquo; &ldquo;Risk Factors&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations,&rdquo; and the <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000141057824001342/tmb-20240630x10q.htm" STYLE="-sec-extract: exhibit">Quarterly
Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2024 filed with the SEC on August&nbsp;13, 2024</A> as well as other sections
in this prospectus and the documents or reports incorporated by reference into this prospectus, discuss some of the factors that could
contribute to these differences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Please consider our
forward-looking statements in light of those risks as you read this prospectus and the documents incorporated by reference into this
prospectus. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or
the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any
forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">You should not assume
that the information contained in this prospectus is accurate as of any date other than as of the date of this prospectus, or that any
information incorporated by reference into this prospectus is accurate as of any date other than the date of the document so incorporated
by reference. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the
reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes
available in the future. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed
or implied in such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If one or more of these
or other risks or uncertainties materializes, or if our underlying assumptions prove to be incorrect, actual results may vary materially
from what we anticipate. All subsequent written and oral forward-looking statements attributable to us or individuals acting on our behalf
are expressly qualified in their entirety by this Note. Before purchasing any securities, you should consider carefully all of the factors
set forth or referred to in this prospectus and the documents incorporated by reference that could cause actual results to differ.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may not actually achieve the plans, intentions
or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements.
Forward-looking statements should be regarded solely as our current plans, estimates and beliefs. We have included important factors
in the cautionary statements included in this document, particularly in the section entitled &ldquo;<I>Risk Factors</I>&rdquo; of this
prospectus that we believe could cause actual results or events to differ materially from the forward-looking statements that we make.
Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for
our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or
combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make.
Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary statement. Our forward-looking statements do not reflect the potential
impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. You should read this prospectus
and the documents that we have filed as exhibits to this prospectus and incorporated by reference herein completely and with the understanding
that our actual future results may be materially different from the plans, intentions and expectations disclosed in the forward-looking
statements we make. The forward-looking statements contained in this prospectus are made as of the date of this prospectus and we do
not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise,
except as required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This summary contains basic information about
us and this offering. Because it is a summary, it does not contain all of the information that you should consider before deciding to
invest in our securities. Before you decide to invest in our securities, you should read this entire prospectus carefully and the documents
incorporated by reference herein, including the information included under the heading titled &ldquo;Risk Factors.&rdquo; Unless we specify
otherwise, all references in this prospectus to &ldquo;Theriva,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;us&rdquo; and &ldquo;our
company&rdquo; refer to Theriva Biologics,&nbsp;Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>The Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a diversified clinical-stage company developing
therapeutics designed to treat cancer and related diseases in areas of high unmet need. As a result of the acquisition in March&nbsp;2022
of Theriva Biologics, S.L. (&ldquo;VCN&rdquo;, formerly named VCN Biosciences, S.L.), described in more detail below (the &ldquo;Acquisition&rdquo;),
we began transitioning our strategic focus to oncology, which is now our primary focus, through the development of VCN&rsquo;s new oncolytic
adenovirus platform designed for intravenous and intravitreal delivery to trigger tumor cell death, to improve access of co-administered
cancer therapies to the tumor, and to promote a robust and sustained anti-tumor response by the patient&rsquo;s immune system. Our lead
product candidate, VCN-01, a clinical stage oncolytic human adenovirus that is modified for tumor-selective replication and to express
an enzyme, PH20 hyaluronidase, is currently being evaluated in a Phase 2 clinical study for the treatment of pancreatic cancer (&ldquo;Virage&rdquo;),
and has recently been used to treat patients in a Phase 1 clinical study for the treatment of retinoblastoma, and Phase 1 clinical studies
for the treatment of other solid tumors including head and neck squamous cell carcinoma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the Acquisition, our focus was on developing
therapeutics designed to treat gastrointestinal (GI) diseases which included our clinical development candidates: (1)&nbsp;SYN-004 (ribaxamase)
which is designed to degrade certain commonly used intravenous (IV)&nbsp;beta-lactam antibiotics within the GI tract to prevent microbiome
damage, thereby preventing overgrowth and infection by pathogenic organisms such&nbsp;<I>Clostridioides difficile</I>&nbsp;infection
(CDI) and vancomycin resistant Enterococci (VRE), and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD)
in allogeneic hematopoietic cell transplant (HCT) recipients, and (2)&nbsp;SYN-020, a recombinant oral formulation of the enzyme intestinal
alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. As part of our strategic
transformation into an oncology focused company, we are exploring value creation options for our SYN-004 and SYN-020 assets, including
out-licensing or partnering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Current Product Pipeline</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm242356_5d2s1aimg003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>*Based on management&rsquo;s current beliefs and expectations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Defined
terms. allo-HCT&nbsp;allogeneic hematopoietic cell transplant.&nbsp;CSR&nbsp;clinical study report.&nbsp;HNSCC&nbsp;head and neck squamous
cell carcinoma.&nbsp;IV&nbsp;intravenous.&nbsp;IVit&nbsp;intravitreal</FONT>.&nbsp;For other abbreviations see the text.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&sup1;Additional products with preclinical proof-of-concept
include SYN-006 (carbapenemase) to prevent aGVHD and infection by carbapenem resistant enterococci and SYN-007 (ribaxamase) DR to prevent
antibiotic associated diarrhea with oral &beta;-lactam antibiotics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&sup2;Depending on funding/partnership. SYN-004 may enter an FDA-agreed
Phase 3 clinical trial for the treatment of CDI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our predecessor, Sheffield
Pharmaceuticals,&nbsp;Inc., was incorporated in 1986, and in 2006 engaged in a reverse merger with Pipex Therapeutics,&nbsp;Inc., a publicly-traded
Delaware corporation formed in 2001. After the reverse merger, we changed our name to Pipex Pharmaceuticals,&nbsp;Inc., and in October&nbsp;2008
we changed our name to Adeona Pharmaceuticals,&nbsp;Inc. On October&nbsp;15, 2009, we engaged in a merger with a wholly owned subsidiary
for the purpose of reincorporating in the State of Nevada. On February&nbsp;15, 2012, we changed our name to Synthetic Biologics,&nbsp;Inc.
On August&nbsp;10, 2018, we effected a one for thirty-five reverse stock split of our authorized, issued and outstanding Common Stock.
On July&nbsp;15, 2022, we effected a one for ten reverse stock split of our authorized, issued and outstanding Common Stock. On October&nbsp;12,
2022, we changed our name to Theriva Biologics,&nbsp;Inc. On August&nbsp;26, 2024, we effected a one for twenty-five reverse stock split
of our authorized, issued and outstanding Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
principal executive offices are located at 9605 Medical Center Drive, Suite&nbsp;270, Rockville, Maryland 20850, and our telephone number
is (301) 417-4367. Our website address is </FONT><I><U>www.therivabio.com</U></I>. <FONT STYLE="background-color: white">Information
contained on our website is intended for informational purposes only and is not incorporated by reference into this prospectus, and it
should not be considered to be part of this prospectus or the&nbsp;</FONT>registration statement of which this prospectus forms a part.
The SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers like
us that file documents electronically with the SEC. The address of the SEC website is&nbsp;<I>www.sec.gov</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Smaller Reporting Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a &ldquo;smaller reporting company&rdquo;
as defined in the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). As a result, we may take advantage of
certain reduced disclosure obligations available to smaller reporting companies, including the exemption from compliance with the auditor
attestation requirements pursuant to the Sarbanes-Oxley Act of 2022, reduced disclosure about our executive compensation arrangements
and the requirements to provide only two years of audited financial statements in our annual reports and registration statements. We
will continue to be a &ldquo;smaller reporting company&rdquo; as long as (1)&nbsp;we have a public float (i.e., the market value of our
common stock held by non-affiliates) less than $250 million calculated as of the last business day of our most recently completed second
fiscal quarter, or (2)&nbsp;our annual revenues are less than $100 million for our previous fiscal year and we have either no public
float or a public float of less than $700 million as of the end of that fiscal year&rsquo;s second fiscal quarter. Decreased disclosures
in our SEC filings due to our status as a &ldquo;smaller reporting company&rdquo; may make it harder for investors to analyze our results
of operations and financial prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004"></A>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>All share information presented herein reflects
a 1-for-25 reverse stock split of our Common Stock, which was effected on&nbsp;August&nbsp;26, 2024.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities offered by us:</B></FONT></TD>
<TD STYLE="width: 76%; text-align: justify">918,600 shares of Common Stock and accompanying Common Warrants to purchase up to
918,600 shares of Common Stock and Pre-Funded Warrants to purchase up to 510,000 shares of Common Stock, together with accompanying
Common Warrants to purchase up to 1,428,600 shares of Common Stock on a reasonable &ldquo;best efforts&rdquo; basis. The shares of
Common Stock or the Pre-Funded Warrants, and accompanying Common Warrants are immediately separable and will be issued separately in
this offering, but must initially be purchased together in this offering. The Common Warrants are exercisable immediately, have an
exercise price of $2.00 per share, and will expire five years after the date of issuance. This prospectus also relates to the offering
of the shares of Common Stock issuable upon exercise of the Common Warrants and Pre-Funded Warrants. For more information regarding
the Common Warrants and Pre-Funded Warrants, you should carefully read the section titled &ldquo;<I>Description of Securities to be
Registered</I>&rdquo; in this prospectus.</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pre-funded warrants offered by us in this offering</B></FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are also offering Pre-Funded Warrants to each purchaser whose purchase
of shares of Common Stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties,
beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Common Stock immediately following
the consummation of this offering in lieu of shares of Common Stock that would otherwise result in the purchaser&rsquo;s beneficial ownership
exceeding 4.99% of our outstanding Common Stock (or, at the election of the purchaser, 9.99%). The Pre-Funded Warrants and accompanying
Common Warrants are immediately separable and will be issued separately in this offering, but must initially be purchased together in
this offering. The purchase price of each Pre-Funded Warrant and accompanying Common Warrant is $1.7499, which is equal to the price of
one share of Common Stock and accompanying Common Warrant in this offering, minus $0.0001. The Pre-Funded Warrants will be exercisable
immediately, have an exercise price of $0.0001 per share, and may be exercised at any time until all of the Pre-Funded Warrants are exercised
in full. For more information regarding the Pre-Funded Warrants, you should carefully read the section titled &ldquo;<I>Description of
Securities to be Registered</I>&rdquo; in this prospectus.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reasonable Best Efforts Offering</B></FONT></TD>
<TD STYLE="text-align: justify">We have agreed to issue and sell the securities offered hereby to the purchasers through the Placement Agent. The Placement Agent is not required to buy or sell any specific number or dollar amount of the securities offered hereby, but will use its reasonable best efforts to solicit offers to purchase the securities offered by this prospectus. See &ldquo;<I>Plan of Distribution</I>&rdquo; beginning on page&nbsp;23 of this prospectus. &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><B>Common stock to be outstanding after this offering</B></TD>
<TD STYLE="text-align: justify">2,272,462 shares (assuming no exercise of the Pre-Funded Warrants or
Common Warrants issued in this offering).&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of proceeds</B></FONT></TD>
<TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.45pt; text-align: justify">We estimate that we will receive approximately
$1.98 million in net proceeds from this offering, after deducting the estimated placement agent fees and estimated offering expenses.</P>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>
    <P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">We currently intend to use the net proceeds from this offering primarily for working capital and general corporate purposes, including for research and development and manufacturing scale-up. We may also use a portion of the net proceeds to invest in or acquire other products, businesses or technologies, although we have no commitments or agreements with respect to any such investments or acquisitions as of the date of this prospectus. See &ldquo;<I>Use of Proceeds</I>&rdquo; for additional information.&nbsp;&nbsp;</P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up</B></FONT></TD>
    <TD STYLE="width: 76%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our directors and
                           officers have agreed with the Placement Agent, subject to certain exceptions, not to sell, transfer or dispose
                           of, directly or indirectly, any of the Common Stock or securities convertible into or exercisable or exchangeable
                           for the Common Stock for a period of 90 days after the completion of this offering. See &ldquo;<I>Plan of
                           Distribution</I>&rdquo; for more information.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk Factors</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You should carefully read
    and consider the information set forth under &ldquo;<I>Risk Factors</I>,&rdquo; together with all of the other information set forth
    in this prospectus, before deciding to invest in shares of the Common Stock.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NYSE American symbol&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Common Stock is listed
    on the NYSE American under the symbol &ldquo;TOVX&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise indicated, the number of
shares of Common Stock to be outstanding immediately after this offering is based on 1,353,862 shares of our Common Stock outstanding
as of September&nbsp;25, 2024 and excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">175,191 </FONT>shares of the Common Stock
    issuable upon the exercise of outstanding stock options with a weighted average exercise price of $41.63 per share; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">112,640 additional shares
    of the Common Stock reserved for future issuance under our equity incentive plans.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Our business, results of operations and financial
condition and the industry in which we operate are subject to various risks. Accordingly, investing in our securities involves a high
degree of risk. This prospectus does not describe all of those risks. You should consider the risk factors described in this prospectus
below, as well as those described under the caption &ldquo;Risk Factors&rdquo; in the documents incorporated by reference herein, including
<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000141057824000293/tmb-20231231x10k.htm" STYLE="-sec-extract: exhibit"><U>our
</U>Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2023</A> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000141057824000601/tmb-20240331x10q.htm" STYLE="-sec-extract: exhibit">our
Quarterly Reports on Form&nbsp;10-Q for the fiscal quarter ended March&nbsp;31, 2024</A> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000141057824001342/tmb-20240630x10q.htm" STYLE="-sec-extract: exhibit">June&nbsp;30,
2024</A>, together with the other information contained or incorporated by reference in this prospectus.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>We have described below and in the documents
incorporated by reference herein the most significant risk factors applicable to us, but they do not constitute all of the risks that
may be applicable to us. New risks may emerge from time to time, and it is not possible for us to predict all potential risks or to assess
the likely impact of all risks. Before making an investment decision, you should carefully consider these risks as well as other information
we include or incorporate by reference in this prospectus. This prospectus also contains forward-looking statements that involve risks
and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of
a number of factors, including the risks described below. See the section titled &ldquo;Special Note Regarding Forward-Looking Statements.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to this Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>We have broad
discretion in the use of the net proceeds from this offering and may not use them effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We will have broad discretion
in the application of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations
or enhance the value of the Common Stock. Our failure to apply these funds effectively could result in financial losses that could have
a material adverse effect on our business, cause the price of our shares of Common Stock to decline and delay the development of our
product candidates. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or
that loses value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>This is a reasonable best efforts offering,
with no minimum amount of securities required to be sold, and we may sell fewer than all of the securities offered hereby.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Placement Agent has agreed to use its reasonable
best efforts to solicit offers to purchase the securities in this offering. The Placement Agent has no obligation to buy any of the securities
from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities. There is no required minimum
number of securities that must be sold as a condition to completion of this offering, and there can be no assurance that the offering
contemplated hereby will ultimately be consummated. Even if we sell securities offered hereby, because there is no minimum offering amount
required as a condition to closing of this offering, the actual offering amount is not presently determinable and may be substantially
less than the maximum amount set forth on the cover page&nbsp;of this prospectus. We may sell fewer than all of the securities offered
hereby, which may significantly reduce the amount of proceeds received by us. Thus, we may not raise the amount of capital we believe
is required for our operations in the short-term and may need to raise additional funds, which may not be available or available on terms
acceptable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Because there is no minimum required for
the offering to close, investors in this offering will not receive a refund in the event that we do not sell an amount of securities
sufficient to pursue the business goals outlined in this prospectus.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not specified a minimum offering amount
nor have or will we establish an escrow account in connection with this offering. Because there is no escrow account and no minimum offering
amount, investors could be in a position where they have invested in our company, but we are unable to fulfill our objectives due to
a lack of interest in this offering. Further, because there is no escrow account in operation and no minimum investment amount, any proceeds
from the sale of securities offered by us will be available for our immediate use, despite uncertainty about whether we would be able
to use such funds to effectively implement our business plan. Investor funds will not be returned under any circumstances whether during
or after the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If the price of the Common Stock fluctuates
significantly, your investment could lose value.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although the Common Stock is listed on the NYSE
American, we cannot assure you that an active public market will continue for the Common Stock. If an active public market for the Common
Stock does not continue, the trading price and liquidity of the Common Stock will be materially and adversely affected. If there is a
thin trading market or &ldquo;float&rdquo; for our stock, the market price for the Common Stock may fluctuate significantly more than
the stock market as a whole. Without a large float, the Common Stock would be less liquid than the stock of companies with broader public
ownership and, as a result, the trading prices of the Common Stock may be more volatile. In addition, in the absence of an active public
trading market, investors may be unable to liquidate their investment in us. Furthermore, the stock market is subject to significant
price and volume fluctuations, and the price of the Common Stock could fluctuate widely in response to several factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our quarterly or annual
    operating results;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in our earnings
    estimates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">investment recommendations
    by securities analysts following our business or our industry;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions or departures
    of key personnel;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">our failure to achieve operating results
        consistent with securities analysts&rsquo; projections;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">results
                                            of our clinical trials; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in industry, general
    market or economic conditions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The stock market has experienced extreme price
and volume fluctuations in recent years that have significantly affected the quoted prices of the securities of many companies, including
companies in our industry. The changes often appear to occur without regard to specific operating performance. The price of the Common
Stock could fluctuate based upon factors that have little or nothing to do with our company and these fluctuations could materially reduce
our stock price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We do not intend to pay dividends on the
Common Stock, so any returns will be limited to increases, if any, in the Common Stock&rsquo;s value. Your ability to achieve a return
on your investment will depend on appreciation, if any, in the price of the Common Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently anticipate that we will retain future
earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for
the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will
depend on, among other factors, our financial condition, operating results, capital requirements, general business conditions and other
factors that our board of directors may deem relevant. Any return to stockholders will therefore be limited to the appreciation in the
value of their stock, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There is no public market for the Common
Warrants or Pre-Funded Warrants to purchase shares of the Common Stock being offered by us in this offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no established public trading market
for the Common Warrants or Pre-Funded Warrants to purchase shares of the Common Stock that are being offered as part of this offering,
and we do not expect a market to develop. In addition, we do not intend to apply to list the Common Warrants or Pre-Funded Warrants on
any national securities exchange or other nationally recognized trading system, including the NYSE American. Without an active market,
the liquidity of the Common Warrants and Pre-Funded Warrants will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The Common Warrants and Pre-Funded Warrants
are speculative in nature.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Warrants and Pre-Funded Warrants offered
hereby do not confer any rights of Common Stock ownership on their holders, such as voting rights, but rather merely represent the right
to acquire shares of the Common Stock at a fixed price. Specifically, commencing on the date of issuance, holders of the Common Warrants
and Pre-Funded Warrants may exercise their right to acquire the shares of the Common Stock upon the payment of an exercise price of $2.00
per share in the case of Common Warrants and an exercise price of $0.0001 per share in the case of Pre-Funded Warrants. Moreover, following
this offering, the market value of the Common Warrants and Pre-Funded Warrants is uncertain and there can be no assurance that the market
value of the Common Warrants or Pre-Funded Warrants will equal or exceed their imputed public offering prices. Furthermore, each Common
Warrant will expire five years from the original issuance date and each Pre-Funded Warrant will not expire until it has been exercised
in full. In the event the price of the Common Stock does not exceed the exercise price of the Common Warrants during the period when
such Common Warrants are exercisable, the Common Warrants may not have any value. There is no established public trading market for the
Common Warrants and Pre-Funded Warrants being offered in this offering, and we do not expect a market to develop. In addition, we do
not intend to apply to list the Common Warrants or Pre-Funded Warrants on any securities exchange or nationally recognized trading system,
including NYSE American. Without an active market, the liquidity of the Common Warrants and Pre-Funded Warrants will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Holders of the Common Warrants and Pre-Funded
Warrants will have no rights as a common stockholder until they acquire shares of the Common Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Warrants and Pre-Funded Warrants in
this offering do not confer any rights of share ownership on their holders, but rather merely represent the right to acquire shares of
the Common Stock at a fixed price. Until holders of the Common Warrants and Pre-Funded Warrants acquire shares of the Common Stock upon
exercise of the Common Warrants and Pre-Funded Warrants, as applicable, holders of Common Warrants and Pre-Funded Warrants will have
no rights with respect to our shares of Common Stock underlying such Common Warrants and Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Provisions of the Common Warrants and Pre-Funded
Warrants offered by this prospectus could discourage an acquisition of us by a third party.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the provisions of our articles
of incorporation, as amended and our second amended and restated bylaws, certain provisions of the Common Warrants and Pre-Funded Warrants
offered by this prospectus could make it more difficult or expensive for a third party to acquire us. The Common Warrants and Pre-Funded
Warrants prohibit us from engaging in certain transactions constituting &ldquo;fundamental transactions&rdquo; unless, among other things,
the surviving entity assumes our obligations under the Common Warrants or Pre-Funded Warrants, as applicable. These and other provisions
of the Common Warrants and Pre-Funded Warrants offered by this prospectus could prevent or deter a third party from acquiring us even
where the acquisition could be beneficial to you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>We may not receive
any additional funds upon the exercise of the Common Warrants or Pre-Funded Warrants.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Each Common Warrant
and each Pre-Funded Warrant may be exercised by way of a cashless exercise under certain circumstances, meaning that the holder may not
pay a cash purchase price upon exercise, but instead would receive upon such exercise the net number of shares of Common Stock determined
according to the formula set forth in the Common Warrant or Pre-Funded Warrant, respectively. Accordingly, we may not receive any additional
funds upon the exercise of the Common Warrants or Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we sell Common Stock or preferred stock
in the future, stockholders may experience immediate dilution and, as a result, our stock price may decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may from time-to-time issue additional shares
of Common Stock or preferred stock at a discount from the current trading price of the Common Stock. As a result, our stockholders could
experience immediate dilution upon the purchase of any shares sold at such discount. In addition, as opportunities present themselves,
we may enter into financing or similar arrangements in the future, including the issuance of debt securities, Common Stock or preferred
stock. If we issue Common Stock or securities convertible into Common Stock, the holders of the Common Stock could experience additional
dilution and, as a result, our stock price may decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, to the extent that any Common Warrants,
Pre-Funded Warrants or options are exercised, new options or restricted stock units are issued under our equity incentive plans, or we
otherwise issue additional shares of Common Stock in the future, at a price less than the public offering price, our stockholders could
experience dilution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Purchasers who
purchase our securities in this offering pursuant to a securities purchase agreement may have rights not available to purchasers that
purchase without the benefit of a securities purchase agreement.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In addition to rights
and remedies available to all purchasers in this offering under federal securities and state law, the purchasers that enter into a securities
purchase agreement will also be able to bring claims of breach of contract against us. The ability to pursue a claim for breach of contract
provides those investors with the means to enforce the covenants uniquely available to them under the securities purchase agreement including,
but not limited to: (i)&nbsp;timely delivery of securities; (ii)&nbsp;agreement to not enter into any financings for 60 days from closing;
and (iii)&nbsp;indemnification for breach of contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Even though the 1-for-25 reverse stock split increased the market
price of our Common Stock, there can be no assurance that our increased stock price will remain at a price that will be sufficient in
order to continue to meet any requirements and policies of the NYSE American or that resulting market price will attract new investors.</I></B>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There can be no assurance that the increased
stock price resulting from the 1-for-25 reverse stock split that we effected on August 26, 2024 will be sufficient in order to allow
us to continue to meet any requirements and policies of the NYSE American or that our Common Stock will remain listed on the NYSE American.
Although we believe that the higher market price of our Common Stock resulting from the reverse stock split may help generate greater
or broader investor interest, there can be no assurance that the resulting share price will attract new investors, including institutional
investors. In addition, there can be no assurance that the market price of our Common Stock will satisfy the investing requirements of
those investors. As a result, the trading liquidity of our Common Stock may not necessarily improve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate that we will receive net proceeds
from this offering of approximately $1.98 million, after deducting the estimated Placement Agent fees and estimated offering expenses
payable by us and assuming no exercise of the Pre-Funded Warrants or Common Warrants.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently intend to use the net proceeds from
this offering primarily for working capital and general corporate purposes, including for research and development and manufacturing
scale-up. We may also use a portion of the net proceeds to invest in or acquire other products, businesses or technologies, although
we have no commitments or agreements with respect to any such investments or acquisitions as of the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These estimates exclude the proceeds, if any,
from the exercise of Common Warrants offered hereby. If all of the Common Warrants offered hereby were to be exercised in cash at the
exercise price of $2.00 per share, we would receive additional proceeds of approximately $2.9 million. We cannot predict when or if
these Common Warrants will be exercised. It is possible that these Common Warrants may expire and may never be exercised. Additionally,
these Common Warrants contain a cashless exercise provision that permit exercise of such Common Warrants on a cashless basis at any time
when there is no effective registration statement under the Securities Act covering the issuance of the underlying shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amounts and timing of any expenditures will
vary depending on the amount of cash generated by our operations, and the rate of growth, if any, of our business, and our plans and
business conditions. The foregoing represents our intentions as of the date of this prospectus based upon our current plans and business
conditions to use and allocate the net proceeds of the offering. However, our management will have significant flexibility and discretion
in the timing and application of the net proceeds of the offering. Unforeseen events or changed business conditions may result in application
of the proceeds of the offering in a manner other than as described in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent that the net proceeds we receive
from the offering are not immediately applied for the above purposes, we plan to invest the net proceeds in short-term, investment-grade,
interest-bearing instruments and U.S. government securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never declared or paid any cash dividends
on the Common Stock and we do not currently intend to pay any cash dividends on the Common Stock in the foreseeable future. We expect
to retain all available funds and future earnings, if any, to fund the development and growth of our business. Any future determination
to pay dividends, if any, on the Common Stock will be at the discretion of our board of directors and will depend on, among other factors,
the terms of any outstanding preferred stock, our results of operations, financial condition, capital requirements and contractual restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>DESCRIPTION OF CAPITAL
STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following is a description of the material
terms of our capital stock. This is a summary only and does not purport to be complete. It is subject to and qualified in its entirety
by reference to our Articles of Incorporation and our Bylaws, each of which are incorporated by reference as an exhibit to the registration
statement of which this prospectus forms a part. We encourage you to read our Articles of Incorporation, our Bylaws and the applicable
provisions of the Nevada Revised Statute (the &ldquo;NRS&rdquo;), for additional information.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized capital stock consists of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,000,000 shares of Common
    Stock, par value $0.001 per share; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000,000 shares of preferred
    stock, par value $0.001 per share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Outstanding Shares</I>. As of September&nbsp;25,
2024, there were 1,353,862 shares of Common Stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Voting
Rights</I></FONT>. The holders of the Common Stock are entitled to one vote for each share held of record on all matters submitted to
a vote of the stockholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the holders of
a majority of the shares of the Common Stock entitled to vote in any election of directors can elect all of the directors standing for
election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Dividend
Rights</I></FONT>. Subject to preferences that may be applicable to any then outstanding preferred stock, the holders of Common Stock
are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Liquidation
Rights</I></FONT>. In the event of our liquidation, dissolution or winding up, holders of the Common Stock will be entitled to share
ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities,
subject to the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Other
Rights and Preferences</I></FONT>. The holders of the Common Stock have no preemptive, conversion or subscription rights, and there are
no redemption or sinking fund provisions applicable to the Common Stock. The rights, preferences and privileges of the holders of the
Common Stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock
that we may designate and issue in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Fully
Paid and Nonassessable</I></FONT>. All of our outstanding shares of Common Stock are fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board of Directors has the authority, without
action by our stockholders, to designate and issue up to 10,000,000 shares of preferred stock in one or more series or classes and to
designate the rights, preferences and privileges of each series or class, which may be greater than the rights of the Common Stock. It
is not possible to state the actual effect of the issuance of any shares of preferred stock upon the rights of holders of the Common
Stock until our Board of Directors determines the specific rights of the holders of the preferred stock. However, the effects might include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricting dividends on
    the Common Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.3in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diluting the voting power
    of the Common Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">impairing liquidation rights of the Common Stock; or</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">delaying or preventing a change in control of us without further action by our stockholders.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors&rsquo; authority to issue
preferred stock without stockholder approval could make it more difficult for a third-party to acquire control of our company and could
discourage such attempt. We have 120,000 shares of preferred stock designated as Series&nbsp;A Convertible Preferred Stock, 15,723 shares
of preferred stock designated as Series&nbsp;B Convertible Preferred Stock, 275,000 shares of preferred stock designated as Series&nbsp;C
Convertible Preferred Stock, and 100,000 shares of preferred stock designated as Series&nbsp;D Convertible Preferred Stock. We currently
do not have any shares of preferred stock outstanding and have no present plans to issue any shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Anti-Takeover Effects of Nevada Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The provisions of NRS, our Articles of Incorporation
and our Bylaws described below may have the effect of delaying, deferring or discouraging another party from acquiring control of us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Business Combinations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The &ldquo;business combination&rdquo; provisions
of Sections 78.411 to 78.444, inclusive, of the NRS generally prohibit a Nevada corporation with at least 200 stockholders from engaging
in various &ldquo;combination&rdquo; transactions with any interested stockholder for a period of two years after the date of the transaction
in which the person became an interested stockholder, unless the transaction is approved by the board of directors prior to the date
the interested stockholder obtained such status or the combination is approved by the board of directors and thereafter is approved at
a meeting of the stockholders by the affirmative vote of stockholders representing at least 60% of the outstanding voting power held
by disinterested stockholders, and extends beyond the expiration of the two-year period, unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 0.25in; padding-left: 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the combination was approved
    by the board of directors prior to the person becoming an interested stockholder or the transaction by which the person first became
    an interested stockholder was approved by the board of directors before the person became an interested stockholder or the combination
    is later approved by a majority of the voting power held by disinterested stockholders; or</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding-left: 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding-left: 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if the consideration to
    be paid by the interested stockholder is at least equal to the highest of: (a)&nbsp;the highest price per share paid by the interested
    stockholder within the two years immediately preceding the date of the announcement of the combination or in the transaction in which
    it became an interested stockholder, whichever is higher, (b)&nbsp;the market value per share of Common Stock on the date of announcement
    of the combination and the date the interested stockholder acquired the shares, whichever is higher, or (c)&nbsp;for holders of preferred
    stock, the highest liquidation value of the preferred stock, if it is higher.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A &ldquo;combination&rdquo; is generally defined
to include mergers or consolidations or any sale, lease exchange, mortgage, pledge, transfer, or other disposition, in one transaction
or a series of transactions, with an &ldquo;interested stockholder&rdquo; having: (a)&nbsp;an aggregate market value equal to 5% or more
of the aggregate market value of the assets of the corporation, (b)&nbsp;an aggregate market value equal to 5% or more of the aggregate
market value of all outstanding shares of the corporation, (c)&nbsp;10% or more of the earning power or net income of the corporation,
and (d)&nbsp;certain other transactions with an interested stockholder or an affiliate or associate of an interested stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In general, an &ldquo;interested stockholder&rdquo;
is a person who, together with affiliates and associates, owns (or within two years, did own) 10% or more of a corporation&rsquo;s voting
stock. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts
to acquire our company even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above
the prevailing market price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Control Share Acquisitions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The &ldquo;control share&rdquo; provisions of
Sections 78.378 to 78.3793, inclusive, of the NRS apply to &ldquo;issuing corporations&rdquo; that are Nevada corporations with at least
200 stockholders, including at least 100 stockholders of record who are Nevada residents, and that conduct business directly or indirectly
in Nevada. The control share statute prohibits an acquirer, under certain circumstances, from voting its shares of a target corporation&rsquo;s
stock after crossing certain ownership threshold percentages, unless the acquirer obtains approval of the target corporation&rsquo;s
disinterested stockholders. The statute specifies three thresholds: one-fifth or more but less than one-third, one-third but less than
a majority, and a majority or more, of the outstanding voting power. Generally, once an acquirer crosses one of the above thresholds,
those shares in an offer or acquisition and acquired within 90 days thereof become &ldquo;control shares&rdquo; and such control shares
are deprived of the right to vote until disinterested stockholders restore the right. These provisions also provide that if control shares
are accorded full voting rights and the acquiring person has acquired a majority or more of all voting power, all other stockholders
who do not vote in favor of authorizing voting rights to the control shares are entitled to demand payment for the fair value of their
shares in accordance with statutory procedures established for dissenters&rsquo; rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A corporation may elect to not be governed by,
or &ldquo;opt out&rdquo; of, the control share provisions by making an election in its articles of incorporation or bylaws, provided
that the opt-out election must be in place on the 10th day following the date an acquiring person has acquired a controlling interest,
that is, crossing any of the three thresholds described above. We have not opted out of the control share statutes, and will be subject
to these statutes if we are an &ldquo;issuing corporation&rdquo; as defined in such statutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The effect of the Nevada control share statutes
is that the acquiring person, and those acting in association with the acquiring person, will obtain only such voting rights in the control
shares as are conferred by a resolution of the stockholders at an annual or special meeting. The Nevada control share law, if applicable,
could have the effect of discouraging takeovers of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Articles of Incorporation and Bylaws</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Articles of Incorporation and Bylaws provide
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the authorized number of directors is determined by
    our board of directors;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">directors may be removed only by the affirmative vote
    of the holders of at least a majority of our voting stock, whether for cause or without cause;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Bylaws may be amended or repealed by our board
    of directors or by the affirmative vote of our stockholders;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">special meetings of the stockholders may be called
    by Chairman of the board, if any, the Vice Chairman of the board, if any, or the President or by any two directors;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our board of directors may fill vacancies on the board
    of directors;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our board of directors
    will be authorized to issue, without stockholder approval, preferred stock, the rights of which will be determined at the discretion
    of the board of directors and that, if issued, could operate as a &ldquo;poison pill&rdquo; to dilute the stock ownership of a potential
    hostile acquirer to prevent an acquisition that our board of directors does not approve;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our stockholders do not
    have cumulative voting rights, and therefore our stockholders holding a majority of the shares of Common Stock outstanding will be
    able to elect all of our directors; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our stockholders must comply
    with advance notice provisions to bring business before or nominate directors for election at a stockholder meeting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Potential Effects of Authorized but Unissued
Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have shares of Common Stock available for
future issuance without stockholder approval. We may utilize these additional shares for a variety of corporate purposes, including future
public offerings to raise additional capital, to facilitate corporate acquisitions or payment as a dividend on the capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The existence of unissued and unreserved Common
Stock may enable our board of directors to issue shares to persons friendly to current management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitations of Director Liability and Indemnification
of Directors, Officers and Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NRS 78.138 provides that directors of a corporation
is not individually liable to the corporation or its stockholders or creditors for any damages as a result of any act or failure to act
in his or her capacity as a director or officer unless: (a)&nbsp;the presumption that directors and officers acted in good faith on an
informed basis with a view toward the best interest of the corporation has been rebutted and (b)&nbsp;it is proven that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The director&rsquo;s or
    officer&rsquo;s act or failure to act constituted a breach of his or her fiduciary duties as a director or officer; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such breach involved intentional
    misconduct, fraud or a knowing violation of law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Articles of Incorporation and Bylaws provide
that we will indemnify our directors and officers to the fullest extent permitted by law and may indemnify employees and other agents.
Our Articles of Incorporation also provide that we are obligated to advance expenses incurred by a director or officer in advance of
the final disposition of any action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have obtained a policy of directors&rsquo;
and officers&rsquo; liability insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into separate indemnification
agreements with our directors and officers. These agreements, among other things, require us to indemnify our directors and officers
for any and all expenses (including reasonable attorneys&rsquo; fees, retainers, court costs, transcript costs, fees of experts, witness
fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees) judgments, fines
and amounts paid in settlement actually and reasonably incurred by such directors or officers or on his or her behalf in connection with
any action or proceeding arising out of their services as one of our directors or officers, or any of our subsidiaries or any other company
or enterprise to which the person provides services at our request provided that such person follows the procedures for determining entitlement
to indemnification and advancement of expenses set forth in the indemnification agreement. We believe that these bylaw provisions and
indemnification agreements are necessary to attract and retain qualified persons as directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The limitation of liability and indemnification
provisions in our Articles of Incorporation and Bylaws may discourage stockholders from bringing a lawsuit against directors for breach
of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an
action, if successful, might provide a benefit to us and our stockholders. Our results of operations and financial condition may be harmed
to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to directors, officers or persons controlling us, we have been informed that, in the opinion
of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At present, there is no pending litigation or
proceeding involving any of our directors or officers as to which indemnification is required or permitted, and we are not aware of any
threatened litigation or proceeding that may result in a claim for indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Listing of the Common Stock on the NYSE American
LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Stock is listed for trading on the
NYSE American LLC under the symbol &ldquo;TOVX.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transfer agent and registrar for the Common
Stock is Equiniti Trust Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stock Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September&nbsp;25, 2024, we had options
outstanding to purchase an aggregate of 175,191 shares of Common Stock that were issued under our equity compensation plans. As of September&nbsp;25,
2024, there were 112,640 shares of Common Stock reserved for future issuance under our equity incentive plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>DESCRIPTION OF SECURITIES
TO BE REGISTERED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are offering 918,600 shares of Common
Stock, Pre-Funded Warrants to purchase up to 510,000 shares of Common Stock, along with Common Warrants to purchase up to 1,428,600
shares of Common Stock. Each share of Common Stock or Pre-Funded Warrant is being sold together with a Common Warrant to purchase
one share of Common Stock. The shares of Common Stock or Pre-Funded Warrants and accompanying Common Warrants will be issued
separately. We are also registering the shares of Common Stock issuable from time to time upon exercise of the Pre-Funded Warrants
offered hereby and the Common Warrants offered hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Common
Stock.</B></FONT> See the description above under &ldquo;Description of Capital Stock- Common Stock&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Common Warrants to
be Issued in this Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following summary of certain terms and
provisions of the Common Warrants included with the Common Stock that are being offered hereby is not complete and is subject to, and
qualified in its entirety by, the provisions of the Common Warrants, the form of which is filed as an exhibit to our registration statement
of which this prospectus forms a part.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Duration and Exercise Price</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Common Warrant offered hereby will be a warrant to purchase one share of Common
Stock and will have an initial exercise price equal to $2.00&nbsp;per share. The Common Warrants will be exercisable immediately upon issuance and will expire five years from the date of issuance. The exercise price
and number of shares of Common Stock issuable upon exercise is subject to appropriate adjustment in the event of share dividends, share
splits, reorganizations or similar events affecting the Common Stock and the exercise price. Subject to the rules&nbsp;and regulations
of the applicable trading market, we may at any time during the term of the Common Warrant, subject to the prior written consent of the
holders, reduce the then current exercise price to any amount and for any period of time deemed appropriate by our board of directors.
The Common Warrants will be issued separately from the shares of Common Stock, or the Pre-Funded Warrants, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Exercisability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Warrants will be exercisable, at the
option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the
number of shares of Common Stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder
(together with its affiliates) may not exercise any portion of the Common Warrant to the extent that the holder would own more than 4.99%
of the outstanding shares of our common warrant immediately after exercise, except that upon at least 61 days&rsquo; prior notice from
the holder to us, the holder may increase the amount of beneficial ownership of outstanding shares after exercising the holder&rsquo;s
Common Warrants up to 9.99% of the number of our shares of Common Stock outstanding immediately after giving effect to the exercise,
as such percentage ownership is determined in accordance with the terms of the Common Warrants. Purchasers of Common Warrants in this
offering may also elect prior to the issuance of the Common Warrants to have the initial exercise limitation set at 9.99% of our outstanding
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cashless Exercise</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If, at the time a holder exercises its Common
Warrants, a registration statement registering the issuance of the shares of Common Stock underlying the Common Warrants under the Securities
Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated
to be made to us upon such exercise in payment of the aggregate exercise price and subject to the nominal value of the shares being paid
up as described below, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares
determined according to a formula set forth in the Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fractional Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No fractional shares of Common Stock or scrip
representing fractional shares will be issued upon the exercise of the Common Warrants. Rather, the number of shares of Common Stock
to be issued will, at our election, either be rounded up to the next whole share or we will pay a cash adjustment in respect of such
final fraction in an amount equal to such fraction multiplied by the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Transferability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to applicable laws, a Common Warrant
may be transferred at the option of the holder upon surrender of the Common Warrant to us together with the appropriate instruments of
transfer and funds sufficient to pay any transfer taxes payable upon such transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Trading Market</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no trading market available for the
Common Warrants on any securities exchange or nationally recognized trading system, and we do not expect a trading market to develop.
We do not intend to list the Common Warrants on any securities exchange or nationally recognized trading market. Without a trading market,
the liquidity of the Common Warrants will be extremely limited. The shares of Common Stock issuable upon exercise of the Common Warrants
are currently traded on the NYSE American.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Right as a Stockholder</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise provided in the Common Warrants
or by virtue of such holder&rsquo;s ownership of Common Stock, the holders of the Common Warrants do not have the rights or privileges
of holders of shares of Common Stock, including any voting rights, until they exercise their Common Warrants. The Common Warrants will
provide that holders have the right to participate in distributions or dividends paid on Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Fundamental Transaction</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a fundamental transaction, as
described in the Common Warrants and generally including (i)&nbsp;our merger or consolidation with or into another person, (ii)&nbsp;the
sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of our assets, (iii)&nbsp;any
purchase offer, tender offer or exchange offer pursuant to which holders of our Common Stock are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of 50% or more of our outstanding Common Stock
or 50% or more of the voting power of our common equity, (iv)&nbsp;any reclassification, reorganization or recapitalization of our shares
of Common Stock or any compulsory share exchange or (v)&nbsp;any stock or share purchase agreement or other business combination with
another person or group of persons whereby such other person or group acquires 50% or more of our outstanding shares of Common Stock
or 50% or more of the voting power of our common equity, the holders will be entitled to receive the number of shares of the Common Stock
for which the Common Warrant is exercisable immediately prior to the occurrence of such fundamental transaction on a net exercise basis.
Notwithstanding the foregoing, in the event of a fundamental transaction, the holders of the Common Warrants have the right to require
us or a successor entity to redeem the Common Warrants for cash in the amount of the Black Scholes Value (as defined in each warrant)
of the unexercised portion of the Common Warrants concurrently with or within 30 days following the consummation of a fundamental transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, in the event of a fundamental transaction
which is not in our control, including a fundamental transaction not approved by our board of directors, the holders of the Common Warrants
will only be entitled to receive from us or our successor entity, as of the date of consummation of such fundamental transaction the
same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of the Common
Warrant that is being offered and paid to the holders of the Common Stock in connection with the fundamental transaction, whether that
consideration is in the form of cash, stock or any combination of cash and stock, or whether the holders of the Common Stock are given
the choice to receive alternative forms of consideration in connection with the fundamental transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Pre-Funded Warrants to be Issued in this Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following summary of certain terms and
provisions of the Pre-Funded Warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety
by, the provisions of the Pre-Funded Warrant, the form of which is filed as an exhibit to our registration statement of which this prospectus
forms a part. Prospective investors should carefully review the terms and provisions of the form of Pre-Funded Warrant for a complete
description of the terms and conditions of the Pre-Funded Warrants.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Duration and Exercise Price</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Pre-Funded Warrant offered hereby will have
an initial exercise price per share equal to $0.0001. The Pre-Funded Warrants will be immediately exercisable and will expire when exercised
in full. The exercise price and number of shares of Common Stock issuable upon exercise is subject to appropriate adjustment in the event
of share dividends, share splits, reorganizations or similar events affecting our shares of Common Stock and the exercise price. Subject
to the rules&nbsp;and regulations of the applicable trading market, we may at any time during the term of the Pre-Funded Warrant, subject
to the prior written consent of the holders, reduce the then current exercise price to any amount and for any period of time deemed appropriate
by our board of directors. The Pre-Funded Warrants will be issued separately from the common warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Exercisability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Pre-Funded Warrants will be exercisable,
at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full
for the number of shares of Common Stock purchased upon such exercise (except in the case of a cashless exercise as discussed below).
A holder (together with its affiliates) may not exercise any portion of the Pre-Funded Warrant to the extent that the holder would own
more than 4.99% of the outstanding shares of the Common Stock immediately after exercise, except that upon at least 61 days&rsquo; prior
notice from the holder to us, the holder may increase the amount of beneficial ownership of outstanding shares after exercising the holder&rsquo;s
Pre-Funded Warrants up to 9.99% of the number of our shares outstanding immediately after giving effect to the exercise, as such percentage
ownership is determined in accordance with the terms of the Pre-Funded Warrants. Purchasers of Pre-Funded Warrants in this offering may
also elect prior to the issuance of the Pre-Funded Warrants to have the initial exercise limitation set at 9.99% of our outstanding shares
of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cashless Exercise</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In lieu of making the cash payment otherwise contemplated
to be made to us upon such exercise of the Pre-Funded Warrants in payment of the aggregate exercise price, the holder may elect instead
to exercise its Pre-Funded Warrants (either in whole or in part), at such time by means of a cashless exercise in which the holder shall
be entitled to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to
a formula set forth in the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fractional Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No fractional shares of Common Stock or scrip
representing fractional shares will be issued upon the exercise of the Pre-Funded Warrants. Rather, the number of shares of Common Stock
to be issued will, at our election, either be rounded up to the next whole share or we will pay a cash adjustment in respect of such
final fraction in an amount equal to such fraction multiplied by the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Transferability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to applicable laws, a Pre-Funded Warrant
may be transferred at the option of the holder upon surrender of the Pre-Funded Warrant to us together with the appropriate instruments
of transfer and funds sufficient to pay any transfer taxes payable upon such transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Trading Market</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no trading market available for the
Pre-Funded Warrants on any securities exchange or nationally recognized trading system, and we do not expect a trading market to develop.
We do not intend to list the Pre-Funded Warrants on any securities exchange or nationally recognized trading market. Without a trading
market, the liquidity of Pre-Funded Warrants will be extremely limited. The shares of Common Stock issuable upon exercise of the Pre-Funded
Warrants are currently traded on the NYSE American.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Right as a Stockholder</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise provided in the Pre-Funded
Warrants or by virtue of such holder&rsquo;s ownership of Common Stock, the holders of the Pre-Funded Warrants do not have the rights
or privileges of holders of the Common Stock, including any voting rights, until they exercise their Pre-Funded Warrants. The Pre-Funded
Warrants will provide that holders have the right to participate in distributions or dividends paid on Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fundamental Transaction</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a fundamental transaction, as
described in the Pre-Funded Warrants and generally including (i)&nbsp;our merger or consolidation with or into another person, (ii)&nbsp;the
sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of our assets, (iii)&nbsp;any
purchase offer, tender offer or exchange offer pursuant to which holders of the Common Stock are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of 50% or more of our outstanding Common Stock
or 50% or more of the voting power of our common equity, (iv)&nbsp;any reclassification, reorganization or recapitalization of our shares
of Common Stock or any compulsory share exchange or (v)&nbsp;any stock or share purchase agreement or other business combination with
another person or group of persons whereby such other person or group acquires 50% or more of our outstanding shares of Common Stock
or 50% or more of the voting power of our common equity, the holders of the Pre-Funded Warrants will be entitled to receive upon exercise
of the Pre-Funded Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised
the Pre-Funded Warrants immediately prior to such fundamental transaction on a net exercise basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_010"></A>MATERIAL UNITED STATES
FEDERAL INCOME TAX CONSIDERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following discussion
describes the material U.S. federal income tax consequences of the acquisition, ownership and disposition of the Common Stock, Pre-Funded
Warrants and Common Warrants acquired in this offering. This discussion is based on the current provisions of the Internal Revenue Code
of 1986, as amended, referred to as the Code, existing and proposed U.S. Treasury regulations promulgated thereunder, and administrative
rulings and court decisions in effect as of the date hereof, all of which are subject to change at any time, possibly with retroactive
effect. No ruling has been or will be sought from the Internal Revenue Service, or IRS, with respect to the matters discussed below,
and there can be no assurance the IRS will not take a contrary position regarding the tax consequences of the acquisition, ownership
or disposition of the Common Stock, Pre-Funded Warrants or Common Warrants, or that any such contrary position would not be sustained
by a court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We assume in this discussion
that the shares of Common Stock, Pre-Funded Warrants and Common Warrants will be held as capital assets (generally, property held for
investment). This discussion does not address all aspects of U.S. federal income taxes, does not discuss the potential application of
the Medicare contribution tax or the alternative minimum tax and does not address state or local taxes or U.S. federal gift and estate
tax laws, except as specifically provided below with respect to non-U.S. holders, or any non-U.S. tax consequences that may be relevant
to holders in light of their particular circumstances. This discussion also does not address the special tax rules&nbsp;applicable to
particular holders, such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons who acquired the
    Common Stock, Pre-Funded Warrants or Common Warrants s as compensation for services;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">traders in securities that
    elect to use a mark-to-market method of accounting for their securities holdings;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons that own, or are
    deemed to own, more than 5% of the Common Stock (except to the extent specifically set forth below);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons required for U.S.
    federal income tax purposes to conform the timing of income accruals to their financial statements under Section&nbsp;451(b)&nbsp;of
    the Code (except to the extent specifically set forth below);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons for whom the Common
    Stock constitutes &ldquo;qualified small business stock&rdquo; within the meaning of Section&nbsp;1202 of the Code or &ldquo;Section&nbsp;1244
    stock&rdquo; for purposes of Section&nbsp;1244 of the Code;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons deemed to sell
    the Common Stock, Pre-Funded Warrants or Common Warrants under the constructive sale provisions of the Code;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">banks or other financial
    institutions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">brokers or dealers in securities
    or currencies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt organizations
    or tax-qualified retirement plans;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pension plans;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulated investment companies
    or real estate investment trusts;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons that hold the Common
    Stock, Pre-Funded Warrants or Common Warrants as part of a straddle, hedge, conversion transaction, synthetic security or other integrated
    investment;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">insurance companies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">controlled foreign corporations,
    passive foreign investment companies, or corporations that accumulate earnings to avoid U.S. federal income tax; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain U.S. expatriates,
    former citizens, or long-term residents of the United States.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In addition, this discussion
does not address the tax treatment of partnerships (including any entity or arrangement classified as a partnership for U.S. federal
income tax purposes) or other pass-through entities or persons who hold shares of Common Stock, Pre-Funded Warrants or Common Warrants
through such partnerships or other entities which are pass-through entities for U.S. federal income tax purposes. If such a partnership
or other pass-through entity holds shares of Common Stock, Pre-Funded Warrants or Common Warrants, the treatment of a partner in such
partnership or investor in such other pass-through entity generally will depend on the status of the partner or investor and upon the
activities of the partnership or other pass-through entity. A partner in such a partnership and an investor in such other pass-through
entity that will hold shares of Common Stock, Pre-Funded Warrants or Common Warrants should consult his, her or its own tax advisor regarding
the tax consequences of the ownership and disposition of shares of Common Stock, Pre-Funded Warrants or Common Warrants through such
partnership or other pass-through entity, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>This discussion of
U.S. federal income tax considerations is for general information purposes only and is not tax advice. Prospective investors should consult
their own tax advisors regarding the U.S. federal, state, local and non-U.S. income and other tax considerations of acquiring, holding
and disposing of the Common Stock, Pre-Funded Warrants and Common Warrants.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For the purposes of
this discussion, a &ldquo;U.S. Holder&rdquo; means a beneficial owner of shares of Common Stock, Pre-Funded Warrants or Common Warrants
that is for U.S. federal income tax purposes (a)&nbsp;an individual citizen or resident of the United States, (b)&nbsp;a corporation
(or other entity taxable as a corporation for U.S. federal income tax purposes), created or organized in or under the laws of the United
States, any state thereof or the District of Columbia, (c)&nbsp;an estate the income of which is subject to U.S. federal income taxation
regardless of its source, or (d)&nbsp;a trust if it (1)&nbsp;is subject to the primary supervision of a court within the United States
and one or more U.S. persons (within the meaning of Section&nbsp;7701(a)(30) of the Code) has the authority to control all substantial
decisions of the trust or (2)&nbsp;has a valid election in effect under applicable U.S. Treasury regulations to be treated as a domestic
trust. A &ldquo;Non-U.S. Holder&rdquo; is, for U.S. federal income tax purposes, a beneficial owner of shares of Common Stock, Pre-Funded
Warrants or Common Warrants that is not a U.S. Holder or a partnership for U.S. federal income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Potential Acceleration
of Income</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Under tax legislation
signed into law in December&nbsp;2017 commonly known as the Tax Cuts and Jobs Act of 2017, U.S. Holders that use an accrual method of
accounting for tax purposes and have certain financial statements generally will be required to include certain amounts in income no
later than the time such amounts are taken into account as revenue in such financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In addition, under the
Inflation Reduction Act signed into law on August&nbsp;16, 2022, certain large corporations (generally, corporations reporting at least
$1 billion average adjusted pre-tax net income on their consolidated financial statements) are potentially subject to a 15% alternative
minimum tax on the &ldquo;adjusted financial statement income&rdquo; of such large corporations for tax years beginning after December&nbsp;31,
2022. The U.S. Treasury Department, the IRS, and other standard-setting bodies are expected to issue guidance on how the alternative
minimum tax provisions of the Inflation Reduction Act will be applied or otherwise administered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The application of these
rules&nbsp;thus may require the accrual of income earlier than would be the case under the general tax rules&nbsp;described below, although
the precise application of these rules&nbsp;is unclear at this time. U.S. Holders that use an accrual method of accounting should consult
with their tax advisors regarding the potential applicability of this legislation to their particular situation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Treatment of Pre-Funded
Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Although it is not entirely
free from doubt, a Pre-Funded Warrants should be treated as a share of Common Stock for U.S. federal income tax purposes and a holder
of Pre-Funded Warrants should generally be taxed in the same manner as a holder of Common Stock, as described below. Accordingly, no
gain or loss should be recognized upon the exercise of a Pre-Funded Warrant and, upon exercise, the holding period of a Pre-Funded Warrant
should carry over to the share of Common Stock received. Similarly, the tax basis of the Pre-Funded Warrant should carry over to the
share of Common Stock received upon exercise, increased by the exercise price of $0.0001 per share. Each holder should consult his, her
or its own tax advisor regarding the risks associated with the acquisition of Pre-Funded Warrants pursuant to this offering (including
potential alternative characterizations). The balance of this discussion generally assumes that the characterization described above
is respected for U.S. federal income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Allocation of Purchase Price</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For U.S. federal income
tax purposes, each share of Common Stock (or, in lieu of Common Stock, each Pre-Funded Warrant t) and the accompanying Common Warrants
issued pursuant to this offering will be treated as an &ldquo;investment unit&rdquo; each of which consisting of one share of Common
Stock or one Pre-Funded Warrant (which, as described above, should generally be treated as a share of Common Stock for U.S. federal income
tax purposes), as applicable and the accompanying Common Warrant to acquire one share of Common Stock. The purchase price for each investment
unit will be allocated between these components in proportion to their relative fair market values at the time the unit is purchased
by the holder. This allocation of the purchase price for each unit will establish the holder&rsquo;s initial tax basis for U.S. federal
income tax purposes in the share of Common Stock (or, in lieu of Common Stock, Pre-Funded Warrant) and the common warrant included in
each unit. The separation of the share of Common Stock (or, in lieu of Common Stock, Pre-Funded Warrant) and the Common Warrant included
in a unit should not be a taxable event for U.S. federal income tax purposes. Each holder should consult his, her or its own tax advisor
regarding the allocation of the purchase price between the Common Stock (or, in lieu of Common Stock, Pre-Funded Warrants) and the Common
Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Tax Considerations
Applicable to U.S. Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Exercise and Expiration
of Common Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Except as discussed
below with respect to the cashless exercise of a Common Warrant, a U.S. Holder generally will not recognize gain or loss for U.S. federal
income tax purposes upon exercise of a Common Warrant. The U.S. Holder will take a tax basis in the shares acquired on the exercise of
a Common Warrant equal to the exercise price of the Common Warrant, increased by the U.S. Holder&rsquo;s adjusted tax basis in the Common
Warrant exercised (as determined pursuant to the rules&nbsp;discussed above). The U.S. Holder&rsquo;s holding period in the shares of
Common Stock acquired on the exercise of a Common Warrant will begin on the date of exercise or possibly the day after such exercise,
and will not include any period for which the U.S. Holder held the Common Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The lapse or expiration
of a Common Warrant will be treated as if the U.S. Holder sold or exchanged the Common Warrant and recognized a capital loss equal to
the U.S. Holder&rsquo;s tax basis in the Common Warrant. The deductibility of capital losses is subject to limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The tax consequences
of a cashless exercise of a Common Warrant are not clear under current tax law. A cashless exercise may be tax-free, either because the
exercise is not a realization event or because the exercise is treated as a recapitalization for U.S. federal income tax purposes. In
either tax-free situation, a U.S. Holder&rsquo;s tax basis in the Common Stock received generally would equal the U.S. Holder&rsquo;s
tax basis in the Common Warrants. If the cashless exercise was not a realization event, it is unclear whether a U.S. Holder&rsquo;s holding
period for the Common Stock would be treated as commencing on the date of exercise of the Common Warrant or the day following the date
of exercise of the Common Warrant. If the cashless exercise were treated as a recapitalization, the holding period of the Common Stock
would include the holding period of the Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">It is also possible
that a cashless exercise could be treated as a taxable exchange in which gain or loss would be recognized. In such event, a U.S. Holder
could be deemed to have surrendered Common Warrants having an aggregate fair market value equal to the exercise price for the total number
of Common Warrants to be exercised. The U.S. Holder would recognize capital gain or loss in an amount equal to the difference between
the fair market value of the Common Stock received in respect of the Common Warrants deemed surrendered and the U.S. Holder&rsquo;s tax
basis in such Common Warrants. Such gain or loss would be long-term or short-term, depending on the U.S. Holder&rsquo;s holding period
in the Common Warrants deemed surrendered. In this case, a U.S. Holder&rsquo;s tax basis in the Common Stock received would equal the
sum of the U.S. Holder&rsquo;s initial investment in the exercised Common Warrants (i.e., the portion of the U.S. Holder&rsquo;s purchase
price for the investment unit that is allocated to the common warrants, as described above under &ldquo;Allocation of Purchase Price&rdquo;)
and the exercise price of such Common Warrants. It is unclear whether a U.S. Holder&rsquo;s holding period for the Common Stock would
commence on the date of exercise of the Common Warrant or the day following the date of exercise of the Common Warrant. There may also
be alternative characterizations of any such taxable exchange that would result in similar tax consequences, except that a U.S. Holder&rsquo;s
gain or loss would be short-term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Due to the absence of
authority on the U.S. federal income tax treatment of a cashless exercise, there can be no assurance which, if any, of the alternative
tax consequences and holding periods described above would be adopted by the IRS or a court of law. Accordingly, U.S. Holders should
consult their tax advisors regarding the tax consequences of a cashless exercise of the Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Distributions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As discussed above,
we currently anticipate that we will retain future earnings, if any, to finance the growth and development of our business and do not
intend to pay cash dividends in respect of shares of Common Stock in the foreseeable future. In the event that we do make distributions
on the Common Stock to a U.S. Holder, those distributions generally will constitute dividends for U.S. tax purposes to the extent paid
out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Distributions in excess
of our current and accumulated earnings and profits will constitute a return of capital that is applied against and reduces, but not
below zero, a U.S. Holder&rsquo;s adjusted tax basis in the Common Stock. Any remaining excess will be treated as gain realized on the
sale or exchange of shares of Common Stock as described below under the section titled &ldquo;&mdash;Disposition of Common Stock, Pre-Funded
Warrants or Common Warrants.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Certain Adjustments
to Pre-Funded Warrants or Common Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The number of shares
of Common Stock issued upon the exercise of the Pre-Funded Warrants or Common Warrants and the exercise price of Pre-Funded Warrants
or Common Warrants are subject to adjustment in certain circumstances. Adjustments (or failure to make adjustments) that have the effect
of increasing a U.S. Holder&rsquo;s proportionate interest in our assets or earnings and profits may, in some circumstances, result in
a constructive distribution to the U.S. Holder. Adjustments to the conversion rate made pursuant to a bona fide reasonable adjustment
formula which has the effect of preventing the dilution of the interest of the holders of Pre-Funded Warrants or Common Warrants generally
should not be deemed to result in a constructive distribution. If an adjustment is made that does not qualify as being made pursuant
to a bona fide reasonable adjustment formula, a U.S. Holder of Pre-Funded Warrants or Common Warrants may be deemed to have received
a constructive distribution from us, even though such U.S. Holder has not received any cash or property as a result of such adjustment.
The tax consequences of the receipt of a distribution from us are described above under &ldquo;Distributions.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Disposition of
Common Stock, Pre-Funded Warrants or Common Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Upon a sale or other
taxable disposition (other than a redemption treated as a distribution, which will be taxed as described above under &ldquo;Distributions&rdquo;)
of shares of Common Stock, Pre-Funded Warrants or Common Warrants, a U.S. Holder generally will recognize capital gain or loss in an
amount equal to the difference between the amount realized and the U.S. Holder&rsquo;s adjusted tax basis in the Common Stock, Pre-Funded
Warrants or Common Warrants sold. Capital gain or loss will constitute long-term capital gain or loss if the U.S. Holder&rsquo;s holding
period for the Common Stock, Pre-Funded Warrants or Common Warrants exceeds one year. The deductibility of capital losses is subject
to certain limitations. U.S. Holders who recognize losses with respect to a disposition of shares of Common Stock, Pre-Funded Warrants
or Common Warrants should consult their own tax advisors regarding the tax treatment of such losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Information Reporting
and Backup Reporting</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Information reporting
requirements generally will apply to payments of distributions (including constructive distributions) on the Common Stock, Pre-Funded
Warrants and Common Warrants and to the proceeds of a sale or other disposition of Common Stock, Pre-Funded Warrants and Common Warrants
paid by us to a U.S. Holder unless such U.S. Holder is an exempt recipient, such as a corporation. Backup withholding will apply to those
payments if the U.S. Holder fails to provide the holder&rsquo;s taxpayer identification number, or certification of exempt status, or
if the holder otherwise fails to comply with applicable requirements to establish an exemption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Backup withholding is
not an additional tax. Rather, any amounts withheld under the backup withholding rules&nbsp;will be allowed as a refund or a credit against
the U.S. Holder&rsquo;s U.S. federal income tax liability provided the required information is timely furnished to the IRS. U.S. Holders
should consult their own tax advisors regarding their qualification for exemption from information reporting and backup withholding and
the procedure for obtaining such exemption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Tax Considerations
Applicable to Non-U.S. Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Exercise and Expiration
of Common Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In general, a Non-U.S.
Holder will not recognize gain or loss for U.S. federal income tax purposes upon the exercise of Common Warrants into shares of Common
Stock, however, to the extent a cashless exercise results in a taxable exchange, the consequences would be similar to those described
in the discussion below under &ldquo;Disposition of Common Stock, Pre-Funded Warrants or Common Warrants&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The expiration of a
Common Warrant will be treated as if the Non-U.S. Holder sold or exchanged Common Warrant and recognized a capital loss equal to the
Non-U.S. Holder&rsquo;s tax basis in the common warrants. However, a Non-U.S. Holder will not be able to utilize a loss recognized upon
expiration of a Common Warrant against the Non-U.S. Holder&rsquo;s U.S. federal income tax liability unless the loss is effectively connected
with the Non-U.S. Holder&rsquo;s conduct of a trade or business within the United States (and, if an income tax treaty applies, is attributable
to a permanent establishment or fixed base in the United States) or is treated as a U.S.-source loss and the Non-U.S. Holder is present
183 days or more in the taxable year of disposition and certain other conditions are met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Certain Adjustments
to Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As described under &ldquo;&mdash;U.S.
Holders&mdash;Certain Adjustments to Pre-Funded Warrants or Common Warrants,&rdquo; an adjustment to the Pre-Funded Warrants or Common
Warrants could result in a constructive distribution to a Non-U.S. Holder, which would be treated as described under &ldquo;Distributions&rdquo;
below. Any resulting withholding tax attributable to deemed dividends would be collected from other amounts payable or distributable
to the Non-U.S. Holder. Non-U.S. Holders should consult their tax advisors regarding the proper treatment of any adjustments to the Pre-Funded
Warrants or Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In addition, regulations
governing &ldquo;dividend equivalents&rdquo; under Section&nbsp;871(m)&nbsp;of the Code may apply to the Pre-Funded Warrants. Under those
regulations, an implicit or explicit payment under Pre-Funded Warrants that references a dividend distribution on the Common Stock would
possibly be taxable to a Non-U.S. Holder as described under &ldquo;Distributions&rdquo; below. Such dividend equivalent amount would
be taxable and subject to withholding whether or not there is actual payment of cash or other property, and the Company may satisfy any
withholding obligations it has in respect of the Pre-Funded Warrants by withholding from other amounts due to the Non-U.S. Holder. Non-U.S.
Holders are encouraged to consult their own tax advisors regarding the application of Section&nbsp;871(m)&nbsp;of the Code to the Pre-Funded
Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Distributions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As discussed above,
we currently anticipate that we will retain future earnings, if any, to finance the growth and development of our business and do not
intend to pay cash dividends in respect of the Common Stock in the foreseeable future. In the event that we do make distributions on
the Common Stock to a Non-U.S. Holder, those distributions generally will constitute dividends for U.S. federal income tax purposes as
described in &ldquo;&mdash;U.S. Holders&mdash;Distributions.&rdquo; To the extent those distributions do not constitute dividends for
U.S. federal income tax purposes (i.e., the amount of such distributions exceeds both our current and our accumulated earnings and profits),
they will constitute a return of capital and will first reduce a Non-U.S. Holder's basis in the Common Stock (determined separately with
respect to each share of Common Stock), but not below zero, and then will be treated as gain from the sale of that share Common Stock
as described below under the section titled &ldquo;&mdash;Disposition of Common Stock, Pre-Funded Warrants or Common Warrants.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Any distribution (including
constructive distributions) on shares of Common Stock that is treated as a dividend paid to a Non-U.S. Holder that is not effectively
connected with the holder&rsquo;s conduct of a trade or business in the United States will generally be subject to withholding tax at
a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and the Non-U.S. Holder&rsquo;s
country of residence. To obtain a reduced rate of withholding under a treaty, a Non-U.S. Holder generally will be required to provide
the applicable withholding agent with a properly executed IRS Form&nbsp;W-8BEN,&nbsp;IRS Form&nbsp;W-8BEN-E or other appropriate form,
certifying the Non-U.S. Holder&rsquo;s entitlement to benefits under that treaty. Such form must be provided prior to the payment of
dividends and must be updated periodically. If a Non-U.S. Holder holds stock through a financial institution or other agent acting on
the holder&rsquo;s behalf, the holder will be required to provide appropriate documentation to such agent. The holder&rsquo;s agent may
then be required to provide certification to the applicable withholding agent, either directly or through other intermediaries. If you
are eligible for a reduced rate of U.S. withholding tax under an income tax treaty, you should consult with your own tax advisor to determine
if you are able to obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim for a refund with the
IRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We generally are not
required to withhold tax on dividends paid (or constructive dividends deemed paid) to a Non-U.S. Holder that are effectively connected
with the holder&rsquo;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty,
are attributable to a permanent establishment or fixed base that the holder maintains in the United States) if a properly executed IRS
Form&nbsp;W-8ECI, stating that the dividends are so connected, is furnished to us (or, if stock is held through a financial institution
or other agent, to the applicable withholding agent). In general, such effectively connected dividends will be subject to U.S. federal
income tax on a net income basis at the regular tax rates applicable to U.S. persons. A corporate Non-U.S. Holder receiving effectively
connected dividends may also be subject to an additional &ldquo;branch profits tax,&rdquo; which is imposed, under certain circumstances,
at a rate of 30% (or such lower rate as may be specified by an applicable treaty) on the corporate Non-U.S. Holder&rsquo;s effectively
connected earnings and profits, subject to certain adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">See also the sections
below titled &ldquo;&mdash;Backup Withholding and Information Reporting&rdquo; and &ldquo;&mdash;Foreign Accounts&rdquo; for additional
withholding rules&nbsp;that may apply to dividends paid to certain foreign financial institutions or non-financial foreign entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Disposition of
Common Stock, Pre-Funded Warrants or Common Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Subject to the discussions
below under the sections titled &ldquo;&mdash;Backup Withholding and Information Reporting&rdquo; and &ldquo;&mdash;Foreign Accounts,&rdquo;
a Non-U.S. Holder generally will not be subject to U.S. federal income or withholding tax with respect to gain recognized on a sale or
other disposition (other than a redemption treated as a distribution, which will be taxable as described above under &ldquo;Distributions&rdquo;)
of shares of Common Stock, Pre-Funded Warrants or Common Warrants unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the gain is effectively
    connected with the Non-U.S. Holder&rsquo;s conduct of a trade or business in the United States, and if an applicable income tax treaty
    so provides, the gain is attributable to a permanent establishment or fixed base maintained by the Non-U.S. Holder in the United
    States; in these cases, the Non-U.S. Holder will be taxed on a net income basis at the regular tax rates and in the manner applicable
    to U.S. persons, and if the Non-U.S. Holder is a corporation, an additional branch profits tax at a rate of 30%, or a lower rate
    as may be specified by an applicable income tax treaty, may also apply;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Non-U.S. Holder is
    a nonresident alien present in the United States for 183 days or more in the taxable year of the disposition and certain other requirements
    are met, in which case the Non-U.S. Holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable
    income tax treaty between the United States and such holder&rsquo;s country of residence) on the net gain derived from the disposition,
    which may be offset by certain U.S.-source capital losses of the Non-U.S. Holder, if any; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Common Stock constitutes
    a U.S. real property interest because we are, or have been at any time during the five-year period preceding such disposition (or
    the Non-U.S. Holder&rsquo;s holding period of the Common Stock, Pre-Funded Warrants or Common Warrants, if shorter), a &ldquo;U.S.
    real property holding corporation,&rdquo; unless the Common Stock is regularly traded on an established securities market, as defined
    by applicable Treasury Regulations, and the Non-U.S. Holder held no more than 5% of our outstanding Common Stock, directly or indirectly,
    during the shorter of the five-year period ending on the date of the disposition or the period that the Non-U.S. Holder held the
    Common Stock. Special rules&nbsp;may apply to the determination of the 5% threshold in the case of a holder of Pre-Funded Warrants
    or Common Warrants. Non-U.S. Holders are urged to consult their own tax advisors regarding the effect of holding Pre-Funded Warrants
    or Common Warrants on the calculation of such 5% threshold. Generally, a corporation is a &ldquo;U.S. real property holding corporation&rdquo;
    if the fair market value of its &ldquo;U.S. real property interests&rdquo; (as defined in the Code and applicable regulations) equals
    or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for
    use in a trade or business. Although there can be no assurance, we believe that we are not currently, and we do not anticipate becoming,
    a &ldquo;U.S. real property holding corporation&rdquo; for U.S. federal income tax purposes. No assurance can be provided that the
    Common Stock will be regularly traded on an established securities market for purposes of the rules&nbsp;described above. Non-U.S.
    Holders are urged to consult their own tax advisors regarding the U.S. federal income tax considerations that could result if we
    are, or become a &ldquo;U.S. real property holding corporation.&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">See the sections titled
 &ldquo;&mdash;Backup Withholding and Information Reporting&rdquo; and &ldquo;&mdash;Foreign Accounts&rdquo; for additional information
regarding withholding rules&nbsp;that may apply to proceeds of a disposition of the Common Stock, Pre-Funded Warrants or Common Warrants
paid to foreign financial institutions or non-financial foreign entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Backup Withholding
and Information Reporting</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We must report annually
to the IRS and to each Non-U.S. Holder the gross amount of the distributions (including constructive distributions) on the Common Stock,
pre-funded warrants or common warrants paid to such holder and the tax withheld, if any, with respect to such distributions. Non-U.S.
Holders may have to comply with specific certification procedures to establish that the holder is not a U.S. person (as defined in the
Code) in order to avoid backup withholding at the applicable rate, currently 24%, with respect to dividends (or constructive dividends)
on the Common Stock, Pre-Funded Warrants or Common Warrants. Generally, a holder will comply with such procedures if it provides a properly
executed IRS Form&nbsp;W-8BEN (or other applicable Form&nbsp;W-8) or otherwise meets documentary evidence requirements for establishing
that it is a Non-U.S. Holder, or otherwise establishes an exemption. Dividends paid to Non-U.S. Holders subject to withholding of U.S.
federal income tax, as described above under the heading &ldquo;<I>Distributions</I>,&rdquo; will generally be exempt from U.S. backup
withholding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Information reporting
and backup withholding generally will apply to the proceeds of a disposition of the Common Stock, pre-funded warrants or common warrants
by a Non-U.S. Holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the holder certifies its status as
a Non-U.S. Holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and
backup withholding will not apply to a payment of disposition proceeds to a Non-U.S. Holder where the transaction is effected outside
the United States through a non-U.S. office of a broker. However, for information reporting purposes, dispositions effected through a
non-U.S. office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions
effected through a U.S. office of a broker. Non-U.S. Holders should consult their own tax advisors regarding the application of the information
reporting and backup withholding rules&nbsp;to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Copies of information
returns may be made available to the tax authorities of the country in which the Non-U.S. Holder resides or is incorporated under the
provisions of a specific treaty or agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Backup withholding is
not an additional tax. Any amounts withheld under the backup withholding rules&nbsp;from a payment to a Non-U.S. Holder can be refunded
or credited against the Non-U.S. Holder&rsquo;s U.S. federal income tax liability, if any, provided that an appropriate claim is timely
filed with the IRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Foreign Accounts</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Foreign Account
Tax Compliance Act, or FATCA, generally imposes a 30% withholding tax on dividends (including constructive dividends) on the Common Stock,
pre-funded warrants and common warrants if paid to a non-U.S. entity unless (i)&nbsp;if the non-U.S. entity is a &ldquo;foreign financial
institution,&rdquo; the non-U.S. entity undertakes certain due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if
the non-U.S. entity is not a &ldquo;foreign financial institution,&rdquo; the non-U.S. entity identifies certain of its U.S. investors,
if any, or (iii)&nbsp;the non-U.S. entity is otherwise exempt under FATCA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Withholding under FATCA
generally will apply to payments of dividends (including constructive dividends) on the Common Stock, Pre-Funded Warrants and Common
Warrants. While withholding under FATCA would have also applied to payments of gross proceeds from a sale or other disposition of the
Common Stock, pre-funded warrants or common warrants, under proposed U.S. Treasury Regulations withholding on payments of gross proceeds
is not required. Although such regulations are not final, applicable withholding agents may rely on the proposed regulations until final
regulations are issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">An intergovernmental
agreement between the United States and an applicable foreign country may modify the requirements described in this section. Under certain
circumstances, a holder may be eligible for refunds or credits of the tax. Holders should consult their own tax advisors regarding the
possible implications of FATCA on their investment in the Common Stock, Pre-Funded Warrants or Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Federal Estate
Tax</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Common Stock owned or
treated as owned by an individual who is not a citizen or resident of the United States (as specially defined for U.S. federal estate
tax purposes) at the time of death will be included in the individual&rsquo;s gross estate for U.S. federal estate tax purposes and,
therefore, may be subject to U.S. federal estate tax, unless an applicable estate tax or other treaty provides otherwise. The foregoing
may also apply to common warrants and pre-funded warrants. A Non-U.S. Holder should consult his, her, or its own tax advisor regarding
the U.S. federal estate tax consequences of the ownership or disposition of shares of the Common Stock, Pre-Funded Warrants and Common
Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>The preceding discussion
of material U.S. federal tax considerations is for information only. It is not tax advice. Prospective investors should consult their
own tax advisors regarding the particular U.S. federal, state, local and non-U.S. tax consequences of purchasing, holding and disposing
of the Common Stock, Pre-Funded Warrants or Common Warrants, including the consequences of any proposed changes in applicable laws.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A.G.P./Alliance
                                            Global Partners has agreed to act as our sole Placement Agent in connection with this offering
                                            subject to the terms and conditions of the placement agency agreement dated September 26, 2024.
                                            The Placement Agent is not purchasing or selling any of the securities offered by this prospectus,
                                            nor is it required to arrange for the purchase and sale of any specific number or dollar
                                            amount of such securities, other than to use its reasonable &ldquo;best efforts&rdquo; to
                                            arrange for the sale of such securities by us. Therefore, we may not sell all of the securities
                                            being offered pursuant to this prospectus. The securities will be offered at a fixed price
                                            and are expected to be issued in a single closing. We will enter into a securities purchase
                                            agreement directly with certain investors, at the investor&rsquo;s option, who purchase our
                                            securities in this offering. Each purchaser with whom we enter into a securities purchase
                                            agreement agrees that for a one-year period from the date of the securities purchase agreement
                                            it shall vote all shares of our common stock over which such purchaser has voting control
                                            at such time in favor of any and all proposals and/or resolutions presented by us to our
                                            stockholders at a meeting of stockholders and any proposal to adjourn any meeting of stockholders
                                            called. Investors who do not enter into a securities purchase agreement shall rely solely
                                            on this prospectus in connection with the purchase of our securities in this offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will deliver the securities being issued to
the investors upon receipt of investor funds for the purchase of the securities offered pursuant to this prospectus. We expect to deliver
the securities being offered pursuant to this prospectus on or about September 27, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Fees and Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to pay the Placement Agent an
aggregate fee equal to 7.0% of the purchase price paid by all purchasers in this offering. In addition, we have agreed to reimburse the
Placement Agent for its legal fees in an amount up to $85,000 and non-accountable expenses of up to $15,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate the total expenses of this offering
paid or payable by us, exclusive of the placement agent fee, will be approximately $350,000. After deducting the fees due to the Placement
Agent and our estimated expenses in connection with this offering, we expect the net proceeds from this offering will be approximately
$1.98 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows the per share and total
cash fees we will pay to the Placement Agent in connection with the sale of the securities pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Per Share of<BR> Common<BR> Stock<BR> and<BR> Accompanying<BR> Common<BR> Warrant</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Per Pre-<BR> Funded<BR> Warrant and<BR> Accompanying<BR> Common<BR> Warrant</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering price <SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1.75</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1.7499</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,499,999</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Placement agent fees</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1225</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1225</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">175,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds before expenses to us <SUP>(2)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.6275</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.6274</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,324,999</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 97%; text-align: justify">The combined public offering price is $1.75 per share of Common Stock and accompanying
    Common Warrant and $1.7499 per Pre-Funded Warrant and accompanying Common Warrant.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="width: 97%; text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Does not include proceeds
                                            from the exercise of the Pre-Funded Warrants or Common Warrants in cash, if any.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Indemnification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to indemnify the Placement Agent
and specified other persons against specified liabilities, including liabilities under the Securities Act, and to contribute to payments
the Placement Agent may be required to make in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Lock-Up Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our directors and officers have entered into
lock-up agreements. Under these agreements, these individuals agreed, subject to specified exceptions, not to sell or transfer any shares
of Common Stock or securities convertible into, or exchangeable or exercisable for, Common Stock during a period ending 90 days after
the completion of this offering, without first obtaining the written consent of the Placement Agent. Specifically, these individuals
agreed, in part, subject to certain exceptions, not to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">offer for sale,
    sell, pledge, or otherwise transfer or dispose of (or enter into any transaction or device that is designed to, or could be expected
    to, result in the transfer or disposition by any person at any time in the future of) any shares of Common Stock or securities convertible
    into or exercisable or exchangeable for Common Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter into
    any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or risks of
    ownership of shares of Common Stock; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make any demand
    for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration
    of any of our securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>No Sales of Similar Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed, subject to certain exceptions,
not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of, any shares of Common Stock (or securities
convertible into or exercisable for Common Stock) or, subject to certain exceptions, file any registration statement, including any amendments
or supplements thereto (other than the registration statement or amendment to the registration statement relating to the securities offered
hereunder and a registration statement on Form&nbsp;S-8), until 60 days after the completion of this offering. We have also agreed, subject to certain exceptions, not
to enter into a variable rate transaction (as defined in the securities purchase agreement) for six months after the completion of this
offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Regulation M</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Placement Agent may be deemed to be an underwriter
within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received by it and any profit realized on the resale
of the shares sold by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act.
As an underwriter, the Placement Agent would be required to comply with the requirements of the Securities Act and the Exchange Act,
including, without limitation, Rule 415(a)(4) under the Securities Act and Rule 10b-5 and Regulation M under the Exchange Act. These
rules and regulations may limit the timing of purchases and sales of shares by the Placement Agent acting as principal. Under these rules
and regulations, the placement agents:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">may
                                            not engage in any stabilization activity in connection with our securities; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">may
                                            not bid for or purchase any of our securities or attempt to induce any person to purchase
                                            any of our securities, other than as permitted under the Exchange Act, until it has completed
                                            its participation in the distribution. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Discretionary Accounts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Placement Agent does not intend to confirm
sales of the securities offered hereby to any accounts over which it has discretionary authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Activities and Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Placement Agent and certain of its affiliates
are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment
banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities.
The Placement Agent and certain of its affiliates have, from time to time, performed, and may in the future perform, various commercial
and investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees
and expenses. For example, A.G.P./Alliance Global Partners is the sales agent under an Amended and Restated Sales Agreement, dated May
2, 2024, with us. Under the Amended and Restated Sales Agreement, we may offer and sell, from time to time, shares of Common Stock through
A.G.P./Alliance Global Partners in an &ldquo;at the market offering&rdquo; as defined in Rule 415(a)(4) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the ordinary course of its various business
activities, the Placement Agent and certain of its affiliates may make or hold a broad array of investments and actively trade debt and
equity securities (or related derivative securities) and financial instruments (including bank loans) for its own account and for the
accounts of its customers, and such investment and securities activities may involve securities and/or instruments issued by us and our
affiliates. If the Placement Agent or its affiliates have a lending relationship with us, they routinely hedge their credit exposure
to us consistent with their customary risk management policies. The Placement Agent and its affiliates may hedge such exposure by entering
into transactions that consist of either the purchase of credit default swaps or the creation of short positions in our securities or
the securities of our affiliates, including potentially the Common Stock offered hereby. Any such short positions could adversely affect
future trading prices of the Common Stock offered hereby. The Placement Agent and certain of its affiliates may also communicate independent
investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities
or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and
instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_012"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Blank Rome LLP, New York, New York will pass upon
certain legal matters relating to the sale of the Common Warrants and Pre-Funded Warrants, offered hereby on our behalf and Parsons Behle&nbsp;&amp;
Latimer, Reno, Nevada will pass on certain legal matters related to the issuance of the Common Stock, Common Warrants and Pre-Funded Warrants
offered hereby on our behalf.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thompson Hine LLP, New York, New York, is acting
as counsel to the Placement Agent in connection with certain legal matters related to this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this prospectus, an attorney
of Blank Rome LLP beneficially owns securities exercisable to purchase shares of the Common Stock that represent less than 1% of our
outstanding shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_013"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements of Theriva
Biologics,&nbsp;Inc. as of December&nbsp;31, 2023 and 2022 and for each of the two years in the period ended December&nbsp;31, 2023 incorporated
by reference in this prospectus and in the registration statement have been so incorporated in reliance on the report of BDO USA, P.C,
an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. The report
on the consolidated financial statements contains an explanatory paragraph regarding the Company&rsquo;s ability to continue as a going
concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_014"></A>WHERE YOU CAN FIND ADDITIONAL
INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have filed with the SEC a registration statement
under the Securities Act for the securities offered by this prospectus. This prospectus, which constitutes a part of the registration
statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith.
For further information about us and the securities offered hereby, we refer you to the registration statement and the exhibits and schedules
filed thereto. Any statements made in this prospectus concerning legal documents are not necessarily complete and you should read the
documents that are filed as exhibits to the registration statement or otherwise filed with the SEC for a more complete understanding
of the document or matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We file annual, quarterly and current reports,
proxy statements and other information with the SEC. Our SEC filings are available to the public at the SEC&rsquo;s website at <I>www.sec.gov</I>.
We are subject to the information and periodic reporting requirements of the Exchange Act, and we file periodic reports, proxy statements
and other information with the SEC. These periodic reports, proxy statements and other information are available at the website of the
SEC referred to above. We maintain a website at&nbsp;<I>https://ir.therivabiologics.com/sec-filings</I>. You may access our Annual Reports
on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q, Current Reports on Form&nbsp;8-K and amendments to those reports filed or furnished
pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Exchange Act with the SEC free of charge at our website as soon as reasonably
practicable after such material is electronically filed with, or furnished to, the SEC. The information contained in, or that can be
accessed through, our website is not incorporated by reference in, and is not part of, this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_015"></A>INCORPORATION OF CERTAIN
INFORMATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEC allows us to &ldquo;incorporate by reference&rdquo;
information from other documents that we file with it, which means that we can disclose important information to you by referring you
to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus
supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incorporate by reference into this prospectus
and the registration statement of which this prospectus is a part the information or documents listed below that we have filed with the
SEC (Commission File No.&nbsp;001-12584):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000141057824000293/tmb-20231231x10k.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></A></TD>
    <TD STYLE="width: 94%; text-align: justify"><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000141057824000293/tmb-20231231x10k.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Annual Report on </FONT><FONT STYLE="font-size: 10pt">Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2023 filed with
    the SEC on March&nbsp;25, 2024;</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Quarterly Report on
    <U>Form&nbsp;10-Q</U> for the quarter ended March&nbsp;31, 2024 filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000141057824000601/tmb-20240331x10q.htm" STYLE="-sec-extract: exhibit">May&nbsp;7,
    2024</A> and our Quarterly Report on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000894158/000141057824001342/tmb-20240630x10q.htm">Form
    10-Q</A> for the quarter ended June&nbsp;30, 2024 filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000141057824001342/tmb-20240630x10q.htm" STYLE="-sec-extract: exhibit">August&nbsp;13,
    2024</A>;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Current
    Reports on Form&nbsp;8-K filed with the SEC on </FONT><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924011395/tm245387d1_8k.htm" STYLE="-sec-extract: exhibit">February&nbsp;7,
    2024</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924050037/tm2412300d1_8k.htm" STYLE="-sec-extract: exhibit">April&nbsp;22,
    2024</A> (other than as set forth therein), <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924050307/tm2412300d2_8k.htm" STYLE="-sec-extract: exhibit">April&nbsp;23,
    2024</A> (other than as set forth therein), <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924056146/tm2413223d1_8k.htm" STYLE="-sec-extract: exhibit">May&nbsp;2,
    2024</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924062270/tm2414630d1_8k.htm" STYLE="-sec-extract: exhibit">May&nbsp;16,
    2024</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924064544/tm2415354d1_8k.htm" STYLE="-sec-extract: exhibit">May&nbsp;23,
    2024</A> (other than as set forth therein), <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924084159/tm2420486d1_8k.htm" STYLE="-sec-extract: exhibit">July&nbsp;31,
    2024</A> (other than as set forth therein), <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924090522/tm2421949d1_8k.htm" STYLE="-sec-extract: exhibit">August&nbsp;16,
    2024</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924092644/tm2422579d1_8k.htm" STYLE="-sec-extract: exhibit">August&nbsp;26,
    2024</A>, </FONT> <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924098225/tm2423567d1_8k.htm" STYLE="-sec-extract: exhibit">September
    9, 2024</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924100010/tm2424064d1_8k.htm" STYLE="-sec-extract: exhibit">September
    16, 2024</A> (other than as set forth therein) and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924101892/tm2424516d1_8k.htm">September
    23, 2024</A> (other than as set forth therein);</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000110465924101004/tm2424296d1_pre14a.htm" STYLE="-sec-extract: exhibit">Our
    Preliminary Proxy Statement on Schedule 14A filed with the SEC on September 18, 2024; and</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The description of the
    Common Stock set forth in (i)&nbsp;our registration statements on </FONT><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000089016307000379/s11-7491_8a.htm" STYLE="-sec-extract: exhibit">Form&nbsp;8-A12B,
    filed with the SEC on June&nbsp;20, 2007 (File No.&nbsp;001-12584)</A> and (ii)&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/894158/000141057824000293/tmb-20231231xex4d3.htm" STYLE="-sec-extract: exhibit">Exhibit&nbsp;4.3</A>&mdash;Description
    of Securities to our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2023.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also incorporate by reference any future filings
(other than current reports furnished under Item 2.02 or Item 7.01 of Form&nbsp;8-K and exhibits filed on such form that are related
to such items unless such Form&nbsp;8-K expressly provides to the contrary) made with the SEC pursuant to Sections 13(a), 13(c), 14 or
15(d)&nbsp;of the Exchange Act, including those made (i)&nbsp;on or after the date of the initial filing of the registration statement
of which this prospectus forms a part and prior to effectiveness of such registration statement, and (ii)&nbsp;on or after the date of
this prospectus but prior to the termination of the offering (i.e., until the earlier of the date on which all of the securities registered
hereunder have been sold or the registration statement of which this prospectus forms a part has been withdrawn). Information in such
future filings updates and supplements the information provided in this prospectus. Any statements in any such future filings will automatically
be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to
be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will furnish without charge to each person,
including any beneficial owner, to whom a prospectus is delivered, upon written or oral request, a copy of any or all of the documents
incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated
by reference into such documents. You should direct any requests for documents to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Theriva Biologics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">9605 Medical Center Drive, Suite&nbsp;270</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Rockville, Maryland 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Telephone: (301) 417-4364</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attention: Corporate Secretary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may also access these documents, free of
charge, on the SEC&rsquo;s website at <I>www.sec.gov</I> or on our website at <I>https://ir.therivabio.com/sec-filings</I>. The information
contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus or
any accompanying prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with Rule&nbsp;412 of the Securities
Act, any statement contained in a document incorporated by reference herein shall be deemed modified or superseded to the extent that
a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein
modifies or supersedes such statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on information contained
in, or incorporated by reference into, this prospectus and any prospectus supplement. We have not authorized anyone to provide you with
information different from that contained in this prospectus or incorporated by reference into this prospectus. We are not making offers
to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such
offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such an offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2423565d1_s1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>918,600 Shares of Common Stock&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1,428,600 Common Warrants to Purchase Up to
1,428,600 Shares of Common Stock&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>510,000 Pre-Funded Warrants to Purchase Up to
510,000 Shares of Common Stock&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1,938,600 Shares of Common Stock Underlying
the Common Warrants and Pre-Funded Warrants</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Sole Placement Agent</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>A.G.P.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>September 25</B><B>,
2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2423565d1_s1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2423565d1_s1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  T +0# 2(  A$! Q$!_\0
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M .&*.<$G"G!.:^Y?B5HWA'Q1X+U3PUXWO+3_ (1_64DL+D2LD1B;8$<1[O\
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M^^RO>Y5.$*=E",8IRDFDE;6HKZ/FWN]59ZO75W:))#@;V .X' 7G"L,_=ZX
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+2225K)66BT9__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm242356_5d2s1aimg003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm242356_5d2s1aimg003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %M U(# 2(  A$! Q$!_\0
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M.U06) S@"FFX0'&V3KC_ %;>H'I[_P ST!I+H$VLP&<[&QC.>GL0?R(J7 H
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M:FP/2H9N)H/]X_\ H)H 7[5'G[LO_?IO?V]C^GJ,GVJ/GY9>!G_5-Z ^GO\
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M%G%"F9WCW+,<N@4(P(V]3D]>@]:[JJ6H:;:ZK82V-_ EQ;3 "2-QD-@Y&?Q
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M#>AZJ?\ 9/ITKHHU8034E?[C.<6WH<K<>+]8TVZT^#S;:\$9M(+T1VSD;YL
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M^0?4Z7G_ .!2_P SF9-#UM$W'Q/<'D#_ (]U[G'K3O[!UO\ Z&BX_P# =?\
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M/&_\^_\ R5?Y"Y<)_/\ ^32_S+_]A:U_T-%Q_P" Z_XT?V%K7_0T7'_@.O\
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M:7^9?_L+6O\ H:+C_P !U_QH_L+6O^AHN/\ P'7_ !JA_P +-\,?\_-Q_P"
M[?X4?\+-\,?\_-Q_X#M_A1[/&_\ /O\ \E7^0<N$_G_\FE_F7_["UK_H:+C_
M ,!U_P :/["UK_H:+C_P'7_&J'_"S?#'_/S<?^ [?X4?\+-\,?\ /S<?^ [?
MX4>SQO\ S[_\E7^0<N$_G_\ )I?YE[^P=:_Z&BX_\!U_QJ*+1-9,\ZCQ+."K
M $_9U^;Y1[U6_P"%G>&/^?FX_P# =O\ "H8OB3X:2>=S<W&'8$?Z.W90/2G[
M/&_\^_\ R5?Y!RX3^?\ \FE_F:O]A:U_T-%Q_P" Z_XT?V%K7_0T7'_@.O\
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M7'_@.O\ C1_8&M_]#1<?^ Z_XUTE%'UJIY?<O\@^ITO/_P "E_F<W_8&M_\
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M5#\0&^USXTPBUBGE@P\I6Y)CM?M!/E%>,C"X)SGFI]O6VT^Z/^0_JU'S_P#
MI?YFG_8.M_\ 0T7'_@.O^-']@:W_ -#1<?\ @.O^-8.H^/KJTNE1K50]L&EE
M6WN \,R_8Y9U7>4SU3MCJIY!(J]9^-[NZO8[ Z9!'=O/'$";HF,![8SY+;,Y
M !&,>^:;K5DKV7W1_P @^K4?/_P*7^9H?V!K?_0T7'_@.O\ C1_8&M_]#1<?
M^ Z_XUI:#JO]M>'].U0Q"$WEM'.8M^[9N4'&<#.,]<"M'(]:CZS43MI]T?\
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M_'- $]%%% $-UD6LV,YV-C&<]/;)_+FI1TJ&\_X\Y^,_NV]/3W(_F/K4PZ4
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M!7_R7B_^)H_L/$]U]_\ P _M2CV?]?,]XW>U&[VKP?\ X6+XK_Z"O_DO%_\
M$T?\+%\5_P#05_\ )>+_ .)H_L/$]U]__ #^U*/9_P!?,]XW>U&[VKP?_A8O
MBO\ Z"O_ )+Q?_$T?\+%\5_]!7_R7B_^)H_L/$]U]_\ P _M2CV?]?,]YW>U
M5K?_ (^KO_?7_P!!%>-:5\1]>75;8ZCJ/F69?$J^1&/E/&<A0>,Y_"O4TNIE
M9G209?!) !!XKBQ& JX=I3MJ=-'%TZJ;CT-S-&:QOMUS_P ]/_'11]NN?^>G
M_CHKF]C(V]HC9S1FL;[=<_\ /3_QT4?;KG_GI_XZ*/8R#VB-G-&:QOMUS_ST
M_P#'11]NN?\ GI_XZ*/8R#VB-G-&:QOMUS_ST_\ '11]NN?^>G_CHH]C(/:(
MU9O]1)_NG^5/'2L8WEPP(,G!X/RBC[=<_P#/3_QT4>QD'M$;6:,UC?;KG_GI
M_P".BC[=<_\ /3_QT4>QD'M$;.:,UC?;KG_GI_XZ*/MUS_ST_P#'11[&0>T1
MLYHS6-]NN?\ GI_XZ*/MUS_ST_\ '11[&0>T1LYHS6-]NN?^>G_CHI/MUS_S
MT_\ '11[&0>T1IM_Q^Q?[C?TJ>LRSGDFNQYC9PIQP!Z5IBLY1<79FD6FKH**
M*0]*D8$X%(7P.E8OB74YM.TQY;6ZM(9DP[B=ADQC[VQ<C+>@/!/>N>C\9WE[
MJBQ:?%YMI$1#,[0MOWF,D,P!_=@MA0,'.&S@ 9%K>W17'-.$%.6S=CNPV>U+
MFN,U;7=?$FGC3K6SA$TT:2"Y=B2'#;<X4X7IDYR",=.:N:CJTUM>V>S5805N
M8K>YLE12Q+\'!/S=P1["HI3557AL:^QERJ5UK?\ #OV.HS32^#C%<4_C"[M;
M:6[NQ R10/<-;6R,[A !MW'^$Y8 X#8Y]#C,LO$GC2ZFL/.TV!9KAYY/(,3(
MKVZK&RD%CN#'+ ;MO)&0*UG%PCS/8RPT?K,N6#MOOHM%<](#9/3%.JGIMX;Z
MU6X-M<6V[.([A KXSU(!./QYJY4W3U0-.+L]PHHHH$4;Z_M=+AN[^]E$-K!$
M'ED()"J"V3QS5+3O%VAZLB/9:A'*'E,(RK*=X0N000"/E!.3QQ3/%>E7&N^'
M-8TJT:);B[M/*C:8D("=W4@$X_"LB;P';HEM%#))>C[1)-<R:I.T\DN8'C09
M8'(4L..PR>O6DHVU9#<KZ'8^:N_9D;\9VYY(]<4@N(BH8.A4G:"&&"?2O.+7
MP#K*ZG87%W/I\BV]FMN9%DD#X^R-"4PJKO'F'=N+;L<#;CF*7X>:S-X=M[!I
M;(-%<R.(1-A0CQA<F00@NX(R/D!P<;N,U7+'^87-*VQZ'<:O86NHVFGSW,:7
M=YN\B$GYI-HR2!Z =ZIWOBW0M.UB'2;S4H(;Z;:$B8GDL<*"<8!)Z9(S4%YH
M3R:CH%U$8F;3I/WTTI/FR)Y+H!G!R=SYY([U4N-'UV+Q!/)I[Z2VE7MS'=77
MVR-WF1D5%P@'RD$1K@D@J23SQ22BQWD=09T!8;ERI 8;AQGI2?:(\$[UP #G
M<.AZ&N"7P+?M)+'*;%H1)_K2S&2\4W4<Q:<;,;E5"J\MG<?N@XK&UOP'J5II
MMT]K;6<PD4QF"W5B7W7PE3*A1E5CX/IR!QS34(O[0G*2Z'J']HVOVE;?S5\U
MHFF !XV*0"<]."12_P!H6OVO[+Y\?G^5YVS=SLSC=],@UPL_@C4[K3IHPUA:
M/*DA%O;2L(HR;B*41J=GW"(R&;;U<_*1Q56Z^'NIR:?';PM8&3[(L;/),Q9&
M6Y,VQ6\LY0ABA.!C ^3'R@Y8?S!S2['I$MS%#;O/+(J0HI=G9L*J@9))],5@
MQ>/O"\^GW%]%J\#6]NZ)*P5L@OG;\N,G.#C YP:SM,\-ZG%X;NO#5TUNEE-8
MNBSH[2,DLC/N4;L9105QP,^@'%1WFB>*M5T>ZCU!?#_V[S8FMA;_ &B-<(2<
MF52)$;G(V],'KDT)1ZL')]C4G^('A:WBMI9=8A$=U'YL+JK,K+N*DD@8&""#
MG&"*W&OH%N8X-WSNAD4X.W:"!][IU8<9R<UYQ_PKC6;BRC%YJJM/%8/#MAN9
M8XYY&F>3RY< ,\15@I).X\G&:V/%7A*_\02V\D8L8E6Q%O)$[L5#?:()"!A.
M5Q$PR0.2..3AN,+V3$I3MJCM//C*!PR[#_%GC\Z03QD*=ZX;[OS#GZ5PNH>&
MKRS\%ZIIL-M!.;C5A<V]O$I9%B:Y1@K+C@  E@. ,U):^![J1]]S]BMBUO>H
MBVQ+BSDF9"IARJ\*%)S\IW$X'-3RJVY7,^QVWVB/;N+H%Y&=PQQ2F9 Q4LH8
M#<03R!ZUYE!X*U;3;'3K5K'3KZ;[7)(T4[M);@?9B@+'RQM)//W#V&2?FI)/
MAOK@OK9Q>V5PEO9_91<22,DKK]E,)#*$.[Y\-EF)QQQCFN2/\PN:78]*>^MH
MXVD>>)412[,7& HY)^@IL&H6UP&,4@*AE7<<@,2H88)X;@CIG\\UYY+\.+]Y
MM/1%TQ+>"R2!BC,A1O)>.0!0F) 2P;<Q[8P.M2S^!-7F@F(@T=7G0Q?9S(YB
MM]T$,?G1_NQ^\5HCM&!PQY%+ECW#FEV/1!*C$JK*2.H!_"H[?'F3XQ]\9QC^
MXOI_7!_#!KCM(\%7NE^([#4O-MF6&2^-Q*&/FS+,R&/=\OS$;3G)X)XS796Y
M)>7.?OC')_NK[?X_7L(:2>C+3;6J)Z***0R&[_X\YO\ KFW?V^A_D?H:E'2H
MKL$VDV,YV-TSZ>Q!_45*.E "T444 %)D>HH-<MXMU270KO1=5,SIIZW1M[Y0
M3M$<BG:Y'^RRK[\GUJH0<Y<JW$W979U.Y?4?G1N7U'YUYK82ZIKKZ;9W.MZA
MIT>J6LVJDV\BB7#2+Y<*,P.U51@2!SS3M3UC5=$U[1VM]3;5;"WL99;]R5'F
MQ"55:4!>"R YXZA3W-='U9\W*FKZ_P!7VZ6,_:JU['I&X>HHW#U%>9V/CE--
M^'=K)<7DMQK<UE<3V_F122"0JTF"S 8'W>Y'2K&G3:S'I&LV=OK4ER\-I#=B
M\NU$DB>;&[.J[=HX*J5SP-W0T/#35[]';U\P]JM#T7(/0T5F^'Y7G\.Z;-*[
M/+):1.[,<EF* DG\:TJYFK-HT3NKA1112&17/^I_X$O_ *$*\_UW6M4MM5U]
M8S=K;P310Q78N8XH+4M#&07# G;N;).TCFO0+G_4_P# E_\ 0A4+Z=9R?:@U
MM$PN_P#CX!4$2_*%^;U^4 ?05I3FHO57_P"')DF]CG;CQ/?Q:L]E%9-*D<Z6
MCR>1)@.P4^9NQL"@L/ESG'.>@.;H_B76);31X&^SS7EY;VVZ:7<%R\4[[MH[
M_NAG'7)]JZ\Z-IQNDNC90&=-I5R@)!484_4#@'J*2#1-,M6B:"QMXS#CRBJ
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M@!ZC 9@/]X^M)3IVUB#C+HR/3-6DO=!349H#&^QR\7<%201^8Z5S=QJ&K17
MQ?S.;;2X=0E54!\UA*QD4#'0J"H';CTKL;:QM;.T6TMH(X;=00L4:A5 )R<
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M/#%1WZX-:>L:38:HUM]N+[86+!%D*AP1@JV.JGN.]0?V)X?(VC3K(!CRJQ*
MV3W &",COZ5FU/FNMCKA+#*ERS3<OP7];_F9NNZC=6VL72IJ[V4-OIWVK!2-
MH]V\J 01N;=CH".G')K.T[Q?_:&M7,ES9N/L%I$SJL V02.P5P96&=RMO7 X
MPC9)(P.HO-)T6[NXM1NK:W>XC3RXKAA\R#J-I[$$Y!ZBL/2? ?AO1KZ:[BGO
MI3+)YSQW-X[QM)@Y=EZ.3R<MGVK9J+@[NSMIZ^9PTN:$VWJG^7Z/H;5IKFFS
M)YL) >:<PH%7+RE3C=@<D8YSV%<WK/B>2U\0:BL5Q(HTZ-6:W+ >=\F["\'V
M!)Z9./2NN2'3HIVGCCMTE8;6=5 8CT_3]*PM;\(Z%KM^;J>6:.1L+,MO+M6;
M'3?P>0..U<MJRC=M-_U_P/N/0HO">TM434?OZI[*W1->KOT.ATR\CU#3[:]B
MXCN(EE49Z!AG'ZU=J"VBC@B2*%0D:(%11T"CH!4];J]M3CE:[Y=@HHHIB(1_
MQ\R?[J_S:N6;5YDD_P"/]CJBW7[S3SCY8=^"=N,A0GS;^_XXKJ/^7F3_ '5_
MFU9\>MVTUPL9AFC5Y7@29MNUG3=N'#9'W&Y( X^E:TG:^E_Z?]?(SGZV,J/Q
M)<M);12FS6:>*.00HY\U@X)R@/4*,$GT!Z5#J'BRYTK3Q)/':F96&=TNT.NP
M/@%B/FY[9)QPO7'017FFM)YL-W;,T_1EF4[]HYQSV'7%/:^MS9&[A=;F$#*F
M!E;=VP#G'ZUIS04E^[T^[^O^ 1RRM\17L]1N)]1>":.$1$2&,HQ)PDFP[L^O
M!X]ZP[/7%,2R6^I)>7D9G-U;><K>6JAR-RCE/F"#\:WXM5M29%N#]DDB=8V2
MX95(+#*@$$@Y]C3Y-1M(9S;F:,S8RT:NN5^N3Q^-3%VO>/\ 7X]^@-7L^8QK
MCQ-):7$EI*;1KN)F\U0Q 10BL'/4A?F//HII&UU[GPW<7IN[>-([M(3=6\G[
MLIYB N&/0$$\]O7O6I=:GI1 M9KV'][*8"$FP0VTM@D'*G /I2VDVEVML$@N
M+=(&DVJ[3JWF.1G[Q)+$^_-6G!)/D=]/^")J3;7-IK_P#G[OQ6=+BEFMY5U#
M3WF"PW1E4KG8"R!\@-SP#GJ2.<8I[>+I9+^:SDMEB=5A=4$F74,T8(?'*_?[
M@=."<UNW>L0V4\\4D$[);Q++-(B@K&AW<D9R?NMT!Z582^M'D2/[1")9"P2,
MR+N?:2#@ \]/P[XI\\+:T_Q]/Z8DI7TF<[;^*+J[O%MK?^SY))&1<+(S>2S"
M0E7_ -I=G(XS[51N/&UU<121VL=O!)]C\\EG#-&=@D)QP2N"0#@#CJ>0.FMG
MT>RCENH;JW5'D\MY7N=XW#/R;F8XY)^7WZ5;-[9AYH_M=ONA4-*OF#,8]6]!
M]:?/33NJ8<LVOC.?@\3R&Y6 FU4F9D5'E/F3CS63,8[A0N3U_ <U(NLW]WX>
MNKEDBCG6VBN8S!EL*XW8P1U !K7N-2AC2V:!6NOM+%8O(*D-\I;.20,8![TZ
M#4K241!I4CDE9D2*1@KEE)#*!GD@CM4.4=&H?U_7E^0[.UG(P[O6X95FO(=5
MMAIXF5$F^TA(6.SE?- (')'U/&>U;FBW#7.CVTSN[,Z_>DQD\GGC@_4=>O>E
M6_LY!A+F"0!BC%95(4@$D'GK@&B/5M.D16CO[1@[;5*SJ0QXX'/)Y'YBHEK&
MRB_Z^1:T=VR\<''2ER*S9M:TZW(#WD&[S1"0)%.UR"0K<\'@]:E&I699E^U0
M!U02.AE7*J>A//3WZ5ERRWL:<R[EW(HJH+Z!XX9(Y%D29MB-&P8$X)ZCZ&J<
MFO6Z2&-(;B9U,FY8T!("':QZC/)X R3V%"C)[(.9=S7-06^?,F_WQ_Z"ON?Z
M?3N95;<H(S@\\C%0V_\ K)N1]\>G]Q?;^>?Z!#+%%%% $%[C[%/NQCRVSG&.
MA]>/SXJ8=*BNL_99<9SL;&W.>G;'/Y<U*.E $-S=V]G&)+JXB@0L%#2N%!)Z
M#)[U+UKS[XCVEG+J.G7%]!/Y<<4BQS-I_P!OM]S%?D>$?,&('# CN,UE0ZQX
MP@O]%M#8-I\9@M1#:@N4;)Q*')C<G"XX+H4&"2U=4<,Y04D][F3J6=FCU.&>
M&?<8I4D",48HP.&'4''<>E0ZCIUIJEC-97UO'<6THQ)%(,JP'//X@5Y5=ZCX
M@TF&Y73HYX;675;]Y)44AC)O!C7(BDX;G V_,<#<._11ZIK#>)([;4[O4;24
MBW6&WLK3S(90T8\UF8H<;7W#.X;0!QS3>&E'WHR_S$JJ>C1TVJ:5HNI1V^GZ
MG:V<PY\B&4#=P!G9WX&,X[5-%HNFP/$T5C;QF* V\81,!8R02H XP<"O-]-@
MU";4=!L1?7INQ)JL4UU<0*\EK)A=NUR@P#PW7!SCI@"U<Z_XGN?#LVJQ"ZM\
MW4-G+%LVF%$7]]*"$<C,A(W;6PJ@XYR&Z$M(J>GS_P ^MA*HM['HEEIUGING
M1V%G;QPVD:E4A4?* 3DC'XFJ6F:=H5G;W>FZ7!9QQ%F^TV\!7@L,'<!TX&*I
M>%M8NKO2;"#5"_\ :DL$EQAHV7=&)-JDDJOS;2F>%SDG %<#HMAY6J7-MI5G
M=Q7!L[I9YI-.,%U:N1D*9Q\DV6X!()[@U,*,I.2;V^[U*<UHTCUZV@CMH(X(
M4"11($11T50, ?E4U>8:/<ZZVE32:7?7URUCHL$EK;31J%FG83!E;*!CM*K@
M CH,DYIRZOKLWD0V6I:E+92WUK$;V:V5)E9]_G( 4 VK\O)7@DC)[/ZL[M<R
M#VGD>FT5Y99:[XCM=#DN[BZU"ZDETR67;Y* QNDXC#+B,X^0[CD-T)QVKI?A
M_J6J:AI.H#59999(+^2*%Y4VLT6U&4\JI;[QY*C/I45,.X1<KK0(U%)I6.IN
M?]3_ ,"7_P!"%2U%<?ZG_@2_S%/^;U_2N<U'44GS>OZ4?-Z_I0 M%)\WK^E'
MS>OZ4 +12?-Z_I1\WK^E "T4GS>OZ4?-Z_I0 M%)\WK^E'S>OZ4 +12?-Z_I
M1\WK^E "T4GS>OZ4?-Z_I0 M07O_ !XW'_7-OY&IOF]?TJ"[S]CGSR/+;C\*
M 'Q11^4G[M?NCM3O*C_YYI_WR*2+/E)_NBG_ #>OZ4!8;Y4?_/-/^^11Y4?_
M #S3_OD4[YO7]*/F]?TH ;Y4?_/-/^^11Y4?_/-/^^13OF]?TH^;U_2@!OE1
M_P#/-/\ OD4>5'_SS3_OD4[YO7]*/F]?TH ;Y4?_ #S3_OD5#-'&)H/D7[Q[
M?[)JQ\WK^E0S9\Z#/]X_^@F@"3RH_P#GFG_?-'E1_P#/-/\ OD4[YO7]*/F]
M?TH ;Y4?_/-/^^11Y4?_ #S3_OD4[YO7]*/F]?TH ;Y4?_/-/^^11Y4?_/-/
M^^13OF]?TH^;U_2@!OE1_P#/-/\ OD4>5'_SS3_OD4[YO7]*/F]?TH ;Y4?_
M #S3\JK01H;J[RBG#+CC_9%6OF]?TJO;Y^U76.N]<_\ ?(H G\J/_GFG_?(H
M\J/_ )YI_P!\BG?-Z_I1\WK^E #?*C_YYI_WR*/*C_YYI_WR*=\WK^E'S>OZ
M4 -\J/\ YYI_WR*/*C_YYI_WR*=\WK^E'S>OZ4 -\J/_ )YI_P!\BCRH_P#G
MFG_?(IWS>OZ4?-Z_I0!%+%&(7(1<[3V]J>(H\?ZM?RI)<^3)D_PG^5.&<=:
M$\J/_GFG_?(H\J/_ )YI_P!\BG?-Z_I1\WK^E #?*C_YYI_WR*/*C_YYI_WR
M*=\WK^E'S>OZ4 -\J/\ YYI_WR*/*C_YYI_WR*=\WK^E'S>OZ4 -\J/_ )YI
M_P!\BCRH_P#GFG_?(IWS>OZ4?-Z_I0!7*JM['M4#Y&Z#Z59JNW_'Y%Z[&_I4
M_P WK^E "T4GS>OZ4?-Z_I0!#<0O*N$*#@_>7=VJ$VL^XX>( \C]V.#^7U_.
MKGS>OZ4?-Z_I0!3^R384!XAALG]V.??IUI6M9<R;3$,C"?(/EY^GI5OYO7]*
M/F]?TH I+:7 ))DA.<XQ&!@^O2G-;3ELJT2J.VP<]?;Z5;^;U_2CYO7]* &Q
MH4C53C(4 X&!3Z3YO7]*/F]?TH 6BD^;U_2CYO7]* (L?Z3)C^ZO\VK$'AB"
M*1YK=TANY'F\R=(AN9)"3@G/4$K@_P"S[FML?\?$GKM7^9J3!/I51G*/PLEQ
M3W.3L_!,<,%U%->M)]HCD1F1"A4L(P2"6)_Y9]SSGK6A9^'EMM$ETV:X:X$[
M$RR.6.[../F9CC QUK<VGVHP?;\JTEB*L_B?G]Q$:,([(YG4_!EE>6]O%9NV
MGB(N/W!9=P? ;.UE)/RCDD].AJ=?#9620)>8MR69(S""REOO9;.2/3T]^,;^
M#[48-'UBK:W,'L87O8Y6+P:8Y)I6U%I)97W%VBR2,..<MR<2'I@# P !BKA\
M.LL\,]O>"*2,",Y@# IM12 ">"?+4@]N>#6]@^U&#0Z]26[!481V1BZAHES>
MZA/+'J AMKF!8+B$0[F907Z/GY<AR.AJ ^&0-2M;J.]>-8#(61%(+AG9MI.[
M!'S$<@^HP:Z'!HP:2K32LF-TXO<XX>!<:=+:#59R9'7<TA=P8U5E"X+]<,>^
M.GRU(_@E9#<[M2F598XU"Q IAT*D.<-UR@Z;3C.2>HZW!]ORHP:OZU7_ )OR
M_P O(CZO3[?F<]%X=N+73;*WM-1"7%K,\WGRQ&7>6# C!?/\7=CTJ.X\)K<7
M5G.U],#$V^8*603-O,F<*P ^8GJ&XZ8ZUTN#2;?I4JO43NGK\OZ_R*]C"UK'
M+P^%&M(;H)>M('9WCA"[53*.H !) /S\XPO ^4<TEGX<NKFUNGU*6-;BY\P$
M+$/EW",9P#@']WT!/7K75;31@^U/ZQ5[A[&"V1RJ>#Y$OY[L:EF263>-\);
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M8'L:N,\:-M+@'K@MCOC^=>6ZC\/]=N(%NM]O)<7-U<W5U9!T,<<DH4*5,D;
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M@8]R1CV(I<K87-&BJUK?P7B2- VX1RO"X/!5U.""/\Y!![U)!<PW,9D@D61
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M^WVW_/3_ ,=/^%'V^V_YZ?\ CI_PK'HH]C$/:,V/M]M_ST_\=/\ A1]OMO\
MGI_XZ?\ "L>BCV,0]HS8^WVW_/3_ ,=/^%'V^V_YZ?\ CI_PK'HH]C$/:,U9
M;ZW:)U$G)4@?*?\ "G"_ML?ZS_QTUD44>QB/VC-C[?;?\]/_ !T_X4?;[;_G
MI_XZ?\*QZ*/8Q%[1FQ]OMO\ GI_XZ?\ "C[?;?\ /3_QT_X5CT4>QB'M&;'V
M^V_YZ?\ CI_PH^WVW_/3_P =/^%8]%'L8A[1FQ]OMO\ GI_XZ?\ "C[?;?\
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MUJ5Z*N?V7/\ \]X_^^#_ (T?V7/_ ,]X_P#O@_XUY/M8]SO]G(IT5<_LN?\
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MO\:,7W]ZW_[Y;_&K-% %;%]_>M_^^6_QHQ??WK?_ +Y;_&K-% %;%]_>M_\
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M^V_[Y;_&C_3?[]M_WRW^-8?_  GWA?\ Z"\7_?M_\*/^$^\+_P#07B_[]O\
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M_P#?+?XT[[7!_P ]/T-'VN#_ )Z?H:.5]@YEW&XOO[UO_P!\M_C1B^_O6_\
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M4C(8'(- R'%]_>M_^^6_QHQ??WK?_OEO\:LT4 5L7W]ZW_[Y;_&C%]_>M_\
MOEO\:LT4 5L7W]ZW_P"^6_QII6\/!-L1Z;6_QJW32P! [GI0!2^RS$G]W9<]
M?W1IZQ7:<)]E7Z(1_6IC<P*Q5IHU(Z@L 11]JM_^>\7_ 'V* (\7W]ZW_P"^
M6_QH"7H)(-L,]?E;_&I/M5O_ ,]XO^^Q1]J@)P)XB?\ ?% $"B\\]\-!NVC/
MRG'4X[_6I,7W]ZW_ .^6_P :D7_CY?\ W%_FU2T 5L7W]ZW_ .^6_P :,7W]
MZW_[Y;_&K-% %;%]_>M_^^6_QHQ??WK?_OEO\:LT4 5L7W]ZW_[Y;_&C%]_>
MM_\ OEO\:LT4 5L7W]ZW_P"^6_QHQ??WK?\ [Y;_ !JS10!6Q??WK?\ [Y;_
M !HQ??WK?_OEO\:LT4 5L7W]ZW_[Y;_&C%]_>M_^^6_QJS10!6Q??WK?_OEO
M\:,7W]ZW_P"^6_QJS10!6Q??WK?_ +Y;_&C%]_>M_P#OEO\ &K-% %;%]_>M
M_P#OEO\ &C%]_>M_^^6_QJS10!5(OO[UO_WRW^-/@!#RYS]\8SG^ZO3)_E@?
MCDU.:KVVWS)]N,^8-V,==B]<?UY_#% %BBBB@""]Q]BGW8V^6V=V,=#USQ^?
M%3CI4-WD6DV,YV-C&<]/8$_D#5;5-3CTG39KR1))%CV@1Q*"SLS!0H'J20.M
M-)R:2W8FTE=E^D-8Z:_;RVFFW""4IJ$OE1@ 91MK,0W/&-C XSS2Z5XBT[5M
M+COTN$C0Q"5TE=0T2GNX!.*MTJB5W'38E5(MVN4?%5O=0BRUC3[5[J\LG91"
M@R7212I'X':WX5EP:;)X8U"UF&GW%_:KIPM1]EC#LDF[>Y*D]')SGV^E=A+>
MVD6X2W4*;2 VZ0#&>F?KCBJTFK6(MIYH+B&X,47FE(ITR5]<D@ >Y('O713Q
M%104.6ZVZ]?\NGJ93I1<G*^OR.7N],O);^SU+3]*:TGLM/#6]N<!0V\[H>.,
ME"1[9%7--&IZ=X7L8Y+".2VBTX"6V8-Y[/M/R!<8Y.!SZFNA^WV'G_9S=V_G
M[MGE>:-V[&<8SG-9]]XCM[+4GL?LUU<21HDDI@53Y:L2 <%@S=#]T'%/VU2J
ME3Y+VUZ[?-KOOW[W)Y(P;DY;_P!?H9/@?2KO05N["]LQ'(_ES"Y0DJX*@>7D
M]TQC&>F#6;YOB5YM6*+J2+)I]SL1@Q*3A_W85N!G;TV #ZGFNPMM;L;F^NK(
MR"*XMY_(VRNH,C;0V4&<D8;^=/BU6S,/G3RQVR^:\2^=-'\Q4XX(8CG'3.?4
M \53Q%3VDJDX)MV[^7KO9"5*/(HQEHKF!=QZO;W6HQ))J$EEYUJVY"S2%#GS
MO+(Y[#(7H,XYJ]X.MY[>TU#SH9XO,U":1!."'9"1@GZU?CUBS^UW]O*_D?8V
M19))6"H2ZAA@Y]^^.:JQ^*+!M(.I*LXB^TM:H@0,\D@8J H!/4CCGIUQ4N=6
M<'#DWM_FOO'RPC+F<MKF_17.GQ5!$9%NK2]M987B6:*5$RBR-M5\JQ4KG&=I
M)&>E75URT-U>0O,(DM&1))I654+L,[02>H&,_6N=T:B5VOZ_IFRJP>B9H7/^
MI_X$O_H0JA<ZW8VUS)!+,P9&"R.(F,<9.,!G VJ3D<$]QZU<F=7MPR,&4E2"
M#D$9%<YJFGZD^HW+V5H8YY)$:*[@GVQD84'SXRWS'@C(4Y&.5HI0C)VF[!4E
M)+W3HY+J&WCE>20 1*7?')5?7 YJ*YU.UM+=KB>79&"1RISP<' ZGG_&N830
MKT-.HLE6?_22]Z'7-T'W;$SG=QE<[N!M&/9-5T*\G$@73EN7D)\ERR?Z.?/9
MRW)R-RL.G/R@&M(T:3E9RT^7]?UW(=2=KI'63W<%NT232A#*^Q-Q^\V"<?D#
M3O/B503*H! .2W;UK,UW3_MWV)A:+<^3<[B"%R@*.NX;O0E3Z\<5@6^@ZA=-
M8)?:;&L,$5I#(KR(X<1>9N./3YA@=2.W:IA3A*"DY6[[#E.2E9([/S8\'YQA
M1D\C@>II/.C(4^8N&^Z<CGZ5Q \+WL*6I2RC*K;QB[A#J/M#++DHW//R],\<
M8) -:-MH+LRO)81Q(L=P8(&90+=F*; "N=IX8Y7.-Q JY4:2VG?[O\_GZ>8E
M4F_LG4I(DBY1PP!P2ISS5&YUFPM/,,TQ58P[,VQB $P7.0.@W#/X^AK,\*Z;
M=:7:RP2VQ@BRI176(.3CYLF/Y6'3!(#'G/:H=,TN:1;2*YC$BP_:XKK<V=Q=
MP1GUW#G\:CV5-2=Y72_K]+>HW.;BK+4V[K5K.RE6.>8JQC,O"EMJ @%B1T&6
M')]_0U>%<W;6TNGZ7?RZC&2(H1:0Y.]I8E!"DX_B8L>/I6]9QO%9P1R'+I&H
M8^IQS6<X1CMJ7!M[EBBBBH+"BBB@ JO>_P#'E/\ ]<V_E5BJ][_QY3_]<V_E
M0)['S,GW%^@IU-3[B_04ZOUD^)"BBBF 4G>EI*3 [3X<ZL;759-,D<"&Z&Y
M3_RT'I]1G\A7J(KQOP5IK:CXGMS\PCM?](<K_LD8'XG'ZU[)WKXS.80CBO=W
M:U/9P3;I:BT445Y!V!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,GB:O*FJ;_JYU;S(CQH[A6<X4'N>M2<^]<E'X>U".4+$PACPI#+(3L?R&1F
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M*C^T0_\ /6/_ +Z%'VB'_GK'_P!]"@"2BH_M$/\ SUC_ .^A1]HA_P">L?\
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M (5>\^'_ )ZQ_P#?8H\^'_GK'_WV*/:2[A[*'8H_8KCUB_[Z/^%'V*X]8O\
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M8O FF1A4-WJ;Q*K*L3W;;1N1T8@=B1(>?4 ]<YZ3[1#_ ,]8_P#OH4?:(?\
MGK'_ -]"J).6N/A]IMSGS;_4\%#$42<(GEE44H$50H4^6#@ <D^N*DN/ >EW
M<$4-W<ZA<11>?M26XR 9=V3C'4!V ]!QS72_:(?^>L?_ 'T*/M$/_/6/_OH4
M 0QO'%&D8$I" +GR3SCCL,?EQ4-];V6IV4MG>0R2V\J['0Q.,C\!5S[1#_SU
MC_[Z%'VB'_GK'_WT* 3L[HJVD=G86L5K:0-#!$NU(T@8!1^592W5^#N,6HD
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MUS9Q7%[81W%[#YD=KY+[DW ["&R0W/7..]0\1!.UR7BJ:=KW_JWD=7E?;\J
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M'XP+PMNM-LXECB6/<W)<$\@KO&-K?P\]LUNZ7J#:EIZ7)B>)R2K(P(P02#U
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M^L/_ '[%'V*T_P"?6'_OV*=NN/[D7_?9_P *-UQ_<B_[[/\ A18+(;]BM/\
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M?=QQCIBAM'TMY3*^G6C2'9ES I)VXV\X[8&/3%6-UQ_<B_[[/^%&ZX_N1?\
M?9_PH @;2--D7:^GVK+@C#0J1@@@CIT.3^9]:ABT2P07BR6\<R7<RRRK+&I4
ME554&,8PH1<?2KNZX_N1?]]G_"C=<?W(O^^S_A0!6&C:6$5!IUH%5!&H$*@*
M@;<%'' # ''J,U(NG62E&%K#N3[K;!N'.>O7.><^O-2[KC^Y%_WV?\*-UQ_<
MB_[[/^% %:/1=*A96BTVS1E3RU*P*,+UVCCID#CVIG_"/Z+OW?V18;L@Y^S)
MG(W =O\ ;?\ [Z/J:N;KC^Y%_P!]G_"C=<?W(O\ OL_X4 .CB2%-D:!5R3@#
MUY-/J+=<?W(O^^S_ (4;KC^Y%_WV?\* !?\ CZD_W%_FU2XJL#-Y[_)'NVKG
MYSCJ?:I-UQ_<B_[[/^% $N*,5%NN/[D7_?9_PHW7']R+_OL_X4 28HQ4>ZX_
MN1?]]G_"C=<?W(O^^S_A0!)@4N*BW7']R+_OL_X4;KC^Y%_WV?\ "@"3%&*C
MW7']R+_OL_X4;KC^Y%_WV?\ "@"7%)C-1[KC^Y%_WV?\*-UQ_<B_[[/^% $F
M!2U%NN/[D7_?9_PHW7']R+_OL_X4 2T5%NN/[D7_ 'V?\*-UQ_<B_P"^S_A0
M!+146ZX_N1?]]G_"C=<?W(O^^S_A0!+146ZX_N1?]]G_  HW7']R+_OL_P"%
M $IJO;_ZR;@??'_H"^Y_I].Y=NN/[D7_ 'V?\*;;Y\R;./OC_P!!7V']?KV
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MHO0TIU(U(\T'=!1115ED5S_J?^!+_P"A"LNZ\3Z;97LMK.9U,+*DD@A8QH6
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M.C^V*7\K_ /]8\/_ "2_ ]DR*K6Y_P!*N_\ ?7_T$5Y;I_BO5(K^&2ZOYI(
M_P"\0X(*]/TZUZ+'*W+HY^?!R._''Z8KKP^.IUTW%/0]#"YI2Q*;BFK=S6HK
M,\^7_GHU'GR_\]&KH]LCL^LQ[&G169Y\O_/1J//E_P">C4>V0?68]C3HK,\^
M7_GHU'GR_P#/1J/;(/K,>QIT5F>?+_ST:CSY?^>C4>V0?68]C0F_U$G^Z?Y4
M\=*S#-*007)!H\^7_GHU/VR#ZS'L:=%9GGR_\]&H\^7_ )Z-2]L@^LQ[&G16
M9Y\O_/1J//E_YZ-1[9!]9CV-.BLSSY?^>C4>?+_ST:CVR#ZS'L:=%9GGR_\
M/1J//E_YZ-1[9!]9CV+K_P#'[%_N-_2ILU0MG9[@%B20#UJW,_EPR.!RJEOR
M%:QES*Z-H34U=$F:,UP ^(TCZLVFPZ6\LXE,0VD $@D$]>!P3GTI4^(LAUA-
M,FTR2&=I1$=Q'&3P>O(YS]#73]7J=CD^OX?^;K;9G?9HK*O]873[B6.2$L$M
M7N%8,!N*_P 'U/;Z&H_^$A@+M$%)F6&.4H#G&X@'IS\H923CHPK [;FS2UBM
MK\8BG<+&WEQ>8JB89EX4C82 "I+;=V>M/MM;2_AFGLX_,@A569V?;NW1B08&
M#_"R^G7VH'<UZ*Q4U])+^&U2'=YK1KO#]"Z._3'81G\ZC_X2( NKP"-U95"R
M2;2^2@W+Q\RC?R1W!&*+"N;U%9)U:<7+P"U1BL N-PFX*DD?W?8T66LBZNHX
M)(A"TB*ZAWY<%=WR\?-CH<="#]:+!<UJ*;(Q2-F'4 FA"2H)[C- QB_\?4G^
MXO\ -JEJ$$"YD_W5_FU2[AZT +12;AZT;A0 M%)N'K1N'K0 M%)D49% "T4F
MX4;@.] "T4FX>M&X>M "T4FX>M&10 M%%% !1110 4444 (:A@!#RYSRXQG/
M]U?4_P L?U,YJO;;?,GQC/F#.,==B]<?UY_#% %BBBB@""]V_8I]VW;Y;9W8
MQC!ZYX_/BIQTJ&ZR+28C.=C8QG/3V!/Y#-2CI0 M%%% #9/NUS.K>'KB_OWF
M$MKM<H4E>+]];XQ]QAUYR>>A/>NF?[M8-]?ZA-K']FZ:UM$T<(FDDG1GR"<!
M0 1Z<FN>NH.-IZ^G<YL2J;BE--Z].Y;_ +/7_A(/[2'E8^S>1T^8'=G/TK"@
M\)26[:;.+E%EMY2TX4D+(-SE2/<;R*TM/UYKA;2WFMF-Y()/-\G!1=C;6.2<
MXSR.IJ"?Q1'/I]Q)9QLDT30';, 04DD"YX/!Z\'!'<5A)X>2YGZ_D_T1S3>%
ME'G?K^3^_1?D-N_#MTR$V^I22L\,MO(U[\Y"/MSMVXY&WO3X]*OTU*!WDM9;
M2!%CA1V<,BA<%@.F\\\]AQZU+JFMOIMS?!D5HH+)9U!'.\LR@?3@5F-XCOD\
M.3SRFU2^M[M;>5@-T8#$?-@'I@^O8U$W0A)IWNM?N_K]>AG4EAH3=[W5W]S_
M *:]/(U-!T2?367[1<1S>1;K;0E$*DH"3ELD\G@<>GO6^.M8GAS4KG45N_/:
M*9(I L=Q#&424;03@$GH>.M;E=E#E]FN38[L,H>S7L]@HHHK8Z"*Y_U/_ E_
M]"%9DFMPV]Y>QW+QI'!)'&I4,S$NN0",=?3&:T[G_4_\"7_T(5DSZ"LM_<7/
MGD>=<P7!7;T,8 Q^.*RJ\]ER&-5U$E[-#CXBT\6JW(F8HSM&%$3[]RC+ KC<
M,=^.*9%K\#WERC,OV9%MS',N6WF4D+T]\?G40\/F&0S07C1S_:)IE<QA@!*1
MN7'X#!]J67P_YHNC]M<R3B#YV1<JT3;@2!@')[<5C>OV_K7^OU.=RQ/9?Y[^
M?I_F6I]>L(1(/-9I$D:+8D;,=RC)X )P 1D]*JZ=XEMKJTLFN2(KFX1&:-%9
ME0L<*"P&!D],XS3$\->5<M=+?.+EI'<OY0QM=5#+C_@(P>WO5>V\&VMNT#?:
M#(46)9-\0._9TQG[OOU]L5/-B+Z)6%S8KF7NJW_!+-YXD^Q:S<6#0KB.U\^.
M0M]]\,=A],A2?P-17'B=H8M.F^S*4G@6>Y.[_4HQ09]^6_0U8U+PY;ZI)?/-
M*P^TQ1QKA>8V0L0P/_ OZ=ZJ_P#"&65P&-[++<'R(X(L,4\M43;P ><G)YJ9
M+$W:6W3[_P#+\WU,YK&7:C:W3;O_ $OGW)+_ %^XMM9:PB_LY0%1@;JZ\MG+
M$\*,'.,?J*T+74GN+2]F,04VTTL0 .=VP]?QQ4=CHD5M,99F6XD,,4>7C'!0
M$;A[G-1)HEY#+<"/4O\ 1IYI)7A, )^?J V:TC[9:OK?_@&T573O+6]]--.Q
M6T[7[Z:6Q-[8Q107R%H)(IBV,)OPP(&. ?RJ%?%DBM<)-:)&Z6*W*?.<,Q3?
ML/'!QG\C4\7AB86\$4VJ22BUA>*V"PJ@CW)L+'NQ )QS3[WPK;7Z7RRS,!<+
M$$(7_5&,, 1ZYW$?2L>7$\NF_P NW^9@UC.7W=_.W;_/;_AQ+KQ$]O/8 6RM
M!+"DMS)OP(%<A5/N,D_@":9?^));37/[/2W@8#R\^9/Y;R;CC* C! ^O.#23
M>#+*Z^T->2RS221K%&VXKY2JNT8 .#Z\]ZEN?#;7?[N;49FA<)YR%%.XJ ,H
M3RF=HSC/MC)JFL1K;]/Z\QR^MZ^JMM_7GU_09/XI@@6YB,EM]KBNA EN90'=
M2RC=MZ]"3^%=(ARHS6'+X>@EAN59@))[H7'F^6"R896V@^GRX_&M.S6Y591<
MNK?O6,>!C"9X!]_>MZ7M+^__ %O_ , ZJ7M;OVG];_\  +=5[[_CSF_ZYM_*
MIQ4%[_QZ3?\ 7-OY5N]CH>QX6.@I:D6VN H!MY<CMY9S_*E^SS_\^\W_ 'P?
M\*^#Y)=G^/\ D?E/LI_RO[G_ )$5%2_9Y_\ GWF_[X/^%'V>?_GWF_[X/^%'
M)+L_N?\ D'LJG\K^Y_Y$5%2_9Y_^?>;_ +X/^%'V>?\ Y]YO^^#_ (4<DNS^
MY_Y![*I_*_N?^1%14OV>?_GWF_[X/^%'V>?_ )]YO^^#_A1R2[/[G_D'LJG\
MK^Y_Y$5%2_9Y_P#GWF_[X/\ A0+:X(S]GFX_Z9G_  HY)=G^/^0>RG_*_N9%
M14OV>?\ Y]YO^^#_ (4?9Y_^?>;_ +X/^%')+L_N?^0>RG_*_N?^1%14OV>?
M_GWF_P"^#_A1]GG_ .?>;_O@_P"%')+L_N?^0>RJ?RO[G_D145+]GG_Y]YO^
M^#_A1]GG_P"?>;_O@_X4<DNS^Y_Y![*I_*_N?^1%14OV>?\ Y]YO^^#_ (4?
M9Y_^?>;_ +X/^%')+L_N?^0>RJ?RO[G_ )$5>G>&Y+B70+5KD<[<(>Y0?=)_
M"O/K'3I;R^AMV22-7<!F92,#J3GZ9KU&,P01)$CHJ*H"@L.G:O5RVE).4WZ'
MOY-0J*4INZ6Q-14?G1?\]8_^^A1YT7_/6/\ [Z%>S9GT5GV)**C\Z+_GK'_W
MT*/.B_YZQ_\ ?0HLPL^Q)14?G1?\]8_^^A1YT7_/6/\ [Z%%F%GV)**C\Z+_
M )ZQ_P#?0H\Z+_GK'_WT*+,+/L245&)HB<"1"?\ >%'G1 X,B _[PHLPL^Q)
M14?G1?\ /6/_ +Z%'G1?\]8_^^A19A9]B2BH_.B_YZQ_]]"CSHO^>L?_ 'T*
M+,+/L245'YT7_/6/_OH4>=%_SUC_ .^A19A9]B2BH_.B_P">L?\ WT*/.B_Y
MZQ_]]"BS"S[%JU_UX^AJU<_\>D_^XW\JIV3H\_RNK<'H<U<NO^/.?_KFW\JZ
MJ7PG?0^#4\?GCTS3==OI)[R:VOXYI2"C8!);*X.#MXSGZCZ$TR.QU36[&;[2
MTVJ/<1EOG+ @%B>>^ JC_&MKQ[H=W8ZC)KVGQ"19D"W"XSMQ@AL?AS_^NG_#
M_0+J>[CUS4(C%Y<9CMD(P2"22Q'XG%>TYQ]ESW_KL?/*C/ZQ['EZW_'?UZ'8
M7\5G?:EY#61NIH%1WR^T1AMRJ1_M8+].W?I6>MUI:>0S6[PI%.T F2YR82<C
MYL'(!**.?4=LUMSZ5!<737!9T=XQ')L/$B@Y (([$G!Z\FFIH\*X5Y99H]S$
MQRA2IW;L@C'(^8UY9].8\FH6%NT@:RD'V:#[7Y?GC@ ,<A=W/,?/N0?6K-H=
M.)A:.WEA-Z\D;!9#M<+D;R0<$'@ ^C+V'%@^';;R'@$]R(GMQ;,H<<H%91DD
M9S\Q_&GMH%LR.IEFY<2(<C,;!]_RG' W<X_#I1H!19M/FTE=7:UE3#)C]\59
M=C% =V<# 9OP)S3#-83I.T%E+<):L2"D^<*FT[DYZDCMC.TYZ\Z46APQ6;6B
MW%P8200"P^7#%N./4]\TK:';M+-)YTZF<OY@5P RMC*].G'7J,GGF@#)CUK3
M)1)<V\+39)M68W #8P[88$Y7[I(SR=P_":*[@CNK!8].N#OD,4.^7B,JAR=I
M/!V CU[=ZT!H=L+F.X\R4RQ.&1LCA1NPG3[OSM[].>*+C1(;C:6N+A622216
M1@""ZE3CCL&.* U(UUN"Z"1Q(S"5IHR>!L*#/(]".1[$>M:D?W%_W165-H-L
MIDFAEF@;EL1;0,[ F<;?[H'Y5JQ_<7_=%(#.U2^_LRTO;WRO-\B(/L!QNP6X
MSCBLNQ\6K<1H9+4#,S1,8)A.H C+Y!08)XP1VK7O[&/4K>\LIF98YX@C%#@X
M.[I1+I-M*T1"^6(F9E6,!1ED*']&KGJ1J\UXO0YJD:SG>#TMM\_\B ^(=-#Q
M*9R#+$94)1@&4)O)'']T'^76B3Q!IT5LMQ)*RQ,2%)C;G R3TZ8[_AUJO!X6
MLK2>.6*:Y&Q0 N\8R(O*SG&<[??&><=::?"]G]G$?G3AO-:0R ("20%(QMVC
M@#H,YYSFIO7MLB+XG71?U_3+MQJPBO["WC@:1+LG$P.%4;2P^I./\\53F\0>
M5KXTK[(Q4@$R^<H;D9R$/++QC(]ZTIK"*:2T?+ VK;HP#_LE>?P-4KGPY9W6
MI+>RR7/RNLGDB3$9=>C$=<\#IZ4YJK]E]5]W4JHJ_P!A]5]W7IW'V'B*TOK1
M)P)(]RHQ1E.0'<HOYD54N_%,4-Y'!%;F1&4MYCED'$BQ\?*<\L>1QQ[Y$T/A
MFUMU@6.XN@L00;=RX<(Y=0WR]B3TQQUS4<GA2SDG$KW%V=N0B%UVH#(),#CI
MN7OGC\*S?UEQ5K7,Y?6^1)6N3+XHTDJ2MSD9 &$/S9) QZ\@_P"32W^MO"ML
MEE9/=W-RAD2%F\G"#&68L..HXQWJ&+PQ9003012SHDA&T#80H!)P 5(89)^]
MGMZ"II?#UK):6L"37,#VJE8IX)-L@!ZC.,8/ICM5?OW%WM?^N_EW*_VEQ:=E
MZ>NN]^FUR0:W;+(D,ZRQ3L(R\?EEO*+G"AF&0,G(ZU';^(M.NC$(I)<2A"A:
M%@"')"G..,E3^5)_PCMGYL3+)<*(UC5HQ)Q)Y9RF[(R<'WY[YH@\.6EO#"B/
M-B%8E4LP_P"6;,RYX]7.?PI_O[]!_P"TWZ6&?\)/9RI"ULKR>:T>W>C1@HS[
M=PR.<&I(_$EA/Y7V=GE$DB1@JAX#ABK?3Y3533/"T=M96R7<\DL\2H.'RB[6
MWX7CH3Z\]NE6;7PY:6<(CAFG4)(DB'Y?DVY 'W>1@D$G)YZ]*4?K#UE8B#Q3
MUE8N:=K-EJA86DP<HJL000<-G!Y['!K0'2LS2M(@TE76!Y"K * ^.%'0# 'K
MU.3ZFM)>E=$.;E7/N==/GY5S[CJ***LT"BBB@ -00??ESG[XQG/]U>F?Z<?C
MFIS5>WQYD^ ,[QG&/[B^G]<'\,&@"Q1110!!>?\ 'G/QG]VWIZ>Y'\Q]:F'2
MHKO_ (\YO^N;?R^A_D?H:E'2@!:*** $.,<UF7^C6]]<+<"2>WN%7R_-MY"C
M%.NT^HSS6I28%3**DK,F45)6DC*AT.R@,?EQLJQP/ $W<%6()SWR2.N?6JJ>
M&;%8VC\VY*LD28+C@1ON4=.Q_P YYK?P*-HJ/8T_Y49NA3?V495[H=KJ%R)Y
M][95%>/=\D@5BP##N,FH9?#.FR2,8XC;JQB)CMP$0F-MRG '7G\JV\"C%-TH
M-W:0.A3;NXJXB@9)IU%%:&P4444 17/^I_X$O_H0K*_M::;5I[6WM#)!;R".
M>7S,%25SD+CD#(SSGT!K5N?]3_P)?_0A5=]*L9;T7CVZ&<$-N]2.A(Z$CL3R
M*SFI.W*S*HINW([',GQ3-?:7<O!;R6S"%)HI@=PVEP,'*@!L'H,CGK5F37I;
M6XNXUC:XE-XT4<;R8"A8E<@;5)[] #UZBMA- TJ-)42RC590%8#/0'( ]!GG
M XITNB:;-(9)+5&=I3*6).=Q 4G\0 ".AQ7,J5??F5SE5'$[N2N9T>NW%TT/
MV+3FG4P0SRCS@K(),X"Y&&(P<\CI5[5;]M/MHGB@6:26=($5GV#+'&2<'^5*
M^@Z6_D[K.-O)540')&U>@([@=LYQ4B:9;^4L<BEU6<SKN8_*^[<#U[&M8QJI
M--Z_\-Y>IK&-;E:;U_+;R]3)/B/;J+6LEJOEJSQM(DF[#I&7;C;C'!'4'U K
M+O->OW@ENF#VL+:=]IB2*4$\R* V2O!P>F".?RZG^Q=.^U&Y^RIYI<N2"<;B
M""<=.0>?6HAX=TD1R1BS39(AC8;CRA;=MZ\#/.!TK*5*NU;F,9T<3+121GCQ
M$TFJR645J"H>2)9#*>9$7<0< @#G'7/'2JMIK\ZV5O>7@9RVFM<E(F&USN4
MX(R"<CO@9[]:WTT738[HW*6B+,7,FX9'S$8)QTY!Y]>])%HNG0Q")+9?+$30
MA6)8;&.2N">F:?LZ][\Q3I8AN[DC,?7KB,M#+8J+M;B* QB?*GS 2K;MOMSQ
MVI?^$A$>C37LUMLEBN#;&)7R#('V\-C.,\YQGVK3CT;3XD5$ME $@E!R2=XZ
M$G.3BG_V79?9I;<P*8I9#(ZDDY8G)/USS5<E;7WBN3$:^\OZVZ&%'XEGGDLX
M(+$&>X>6,B20HBF, Y!*9((/!P/IUJ ^*I3=)-Y*K9?V:;QDW?.3NQ@'IU&.
MW7/M711:/I\,EN\=NH>WWF-MQ)!?[Q//)/J<FF#0],7R\6B8CB,"\G_5GJIY
MY'UJ73KO[1#I8G^?^OZW,5?%$TJQ1)8#[2]R+?#2LL9RA8,&*9(X(/'6HHM9
MOC?20)\T7FW>XO+\P$94?+\N,#<,9Z]R,<]!'HFG0B/9;*#')YJMN);?@C))
M.3P<<T-HFG,VXVPW>8\N0Q'S/][OWXR.G%#I5GO(;I8AVO+^OZ_I'/Z;XID)
MTVWG@D"W"1@3S28:0L.J_*%;!X/(/M73W?\ QXW&>?W;=?H:JPZ!I5N\;16B
M(8]NW!./E^Z2,_,1V)R15N\ %C<8_P">;?R-;48U(JTW<VH0JQ5JCN2Q?ZE/
M]T4^F1?ZE/\ =%/K8Z HHHH **** "BBB@ J&;_70?[Q_P#034U03?ZZ#_>/
M_H)H GHHHH **** "BBB@ HHHH ,56M_^/N[_P!]?_015FJUO_Q]W?\ OK_Z
M"* +-%%% !1110 4444 %%%% #)O]1)_NG^5/'2F3?ZB3_=/\J<.E "T444
M%%%% !1110 4444 0-_Q^Q?[C?TJ9E5T96&5(P1ZU"W_ !^Q?[C?TJ>@!I16
M4JP!!X(/-*%50 J@ >@I:* "BBB@ HHHH **** "BBB@!" P((R#P: ,#':E
MHH B4#[3)_N+_-JEP/2HE_X^I/\ <7^;5+0 F!Z"C ]!2T4 )@>E&!Z4M% !
M@>E)@'J!2T4 )M'H*"JGJH/X4M% "8 ["EP/2BB@!,#T%+@>E%% !@>E%%%
M!1110 4444 !J" G?+G/WQC_ +Y7V']?KV$QJ&WSYDV?[X_]!7W/]/IW(!/1
M110!'<*9('13@LI4'GC(]B#^1I@^T9'SQ8_W3ZG^F/UJ>B@"O_I6W[\.<?W3
MUQ]?7/X4O[_=]^+&?[IZ9^OI^M3T4 5_])Q]^'./[IZX/OZX_"E_TC/WXL?[
MI]1[^F?TJ>B@"#_2/[\7_?)]_?Z?K1_I./OQ?]\GT'OZY_2IZ* (/](S]^+&
M?[IZ9/OZ8_&D_P!*V_?AW8_NG&<?7U_2K%% $/[_ '??BQG^Z>F?KZ?K3?\
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M^+_OD^_O]/UJ>B@"#_2<??BS_NGT'OZY_2E_?Y^_'C/]T],G^F/QJ:B@"O\
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5NV>!@#@ ?H!US^6*FHH **** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
